CLINICAL STUDY PROTOCOL: INDV-2000-104 
Protocol Title:  An Open Label, Fixed-sequence Study to 
Evaluate the Potential CYP3A4 Induction Effect of INDV-2000 
using Oral Midazolam as a Probe in Healthy Adults Participants  
Protocol Number:
 INDV-2000-104 
Original Protocol Date:
 15 December  2022
Amendment Number/Date: Amendment 1/ 10 April 2023 
NCT: [STUDY_ID_REMOVED] 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 1 of 80  Clinical Study P rotocol  
 
PROTOCOL TITLE:  
An Open Label, Fixed -sequence Study to Evaluate the Potential CYP3A4 Induction E ffect of 
INDV- 2000 using Oral Midazolam as a Probe in Healthy Adults  Participants  
Protocol Number:  INDV- 2000 -104 
Amendment Number:  1 
Amendment Scope:  Global 
Product: INDV- 2000  
Short  Title:  
Study of potential CYP3A4 induction by INDV -2000 in healthy adults  
Study Phase:  Phase I  
Acronym:  DDI Study  
Sponsor Name: Indivior Inc.  
Legal Registered Address:  
Indivior Inc.  
10710 Midlothian Turnpike, Suite 125  
North Chesterfield, VA 23235 USA  
 Regulatory Agency Identifier Number(s)  
Registry  Identifying Number  
IND 145881  
 Approval Date:  10 Apr 2023  
  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 2 of 80  Sponsor Signator ies: 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 3 of 80  MEDICAL MONITOR NAME AND CONTACT INFORMATI ON 
 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 4 of 80  CONFIDENTIALITY AND INVESTIGATOR STATEMENT  
Protocol Number: INDV -2000- 104 
Protocol Title: An Open Label, Fixed -sequence  Study to Evaluate the Potential CYP3A4 
Induction Effect of INDV -2000 using Oral Midazolam as a Pr obe in Healthy Adults  Participants  
The information contained in this protocol and all other information relevant to this study drug 
is the confidential and proprietary information of Indivior, and except as may be required by 
local laws or regulation, may not be disclosed to others without prior written permission of 
Indivior.  
I have read the protocol, including all appendices, and I agree that it contains all of the necessary information for me and my staff to conduct this study as described. My staff and/or I will conduct this study as outlined herein, in accordance with the regulations stated in the International Council on Harmonisation E6/Good Clinical Practice (ICH  E6/GCP) guidelines and 
will make a reasonable effort to complete the study within the time designated.  
I agree to ensure all associates, colleagues , and employees delegated to assist with the conduct 
of the study are trained on this study protocol and amendments, and other study -related 
materials , and are qualified to perform their delegated tasks. I will provide all study personnel 
copies of the protocol and any amendments , and grant access to all information provided by 
Indivior or specified designees. I will discuss the material with them to ensure that they are fully informed about INDV- 2000 and appropriate information throughout the study. Mechanisms are 
in place to ensure that site staff receives the appropriate information throughout the study.  
 
 
  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 5 of 80  PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  
 
Document History  
Document:  Date  
Amendment 1 10 Apr 2023  
Original Protocol  15 Dec 2022  
 
Amendment 1 (10 Apr 2023)  
 Rationale for the Amendment:  
 
Section Number and Name  Description of Change  Brief Rationale  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 6 of 80  Section Number and Name  Description of Change  Brief Rationale  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 7 of 80  Section Number and Name  Description of Change  Brief Rationale  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 8 of 80  Section Number and Name  Description of Change  Brief Rationale  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 9 of 80  Section Number and Name  Description of Change  Brief Rationale  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 10 of 80 TABLE OF CONTENTS  
 
MEDICAL MONITOR NAME AND CONTACT INFORMATION  .......................................................... 3  
CONFIDENTIALITY AND INVESTIGATOR STATEMENT .................................................................... 4  
PROTOCOL AMENDMENT SUMMARY OF CHANGES TABLE  ........................................................... 5  
TABLE OF CONTENTS  ................................................................................................................... 10 
TABLE OF TABLES  ........................................................................................................................ 13 
TABLE OF FIGURES ...................................................................................................................... 13 
ABBREVIATIONS .......................................................................................................................... 14 
1 PROTOCOL SUMMARY .......................................................................................................... 16 
1.1 Synopsis .......................................................................................................................... 16 
1.2 Schema  ............................................................................................................................ 19 
1.3 Schedule of Events (SoE)  ................................................................................................. 20 
2 INTRODUCTION  ..................................................................................................................... 23 
2.1 Study R ationale  ............................................................................................................... 23 
2.2 Background ..................................................................................................................... 23 
2.2.1  INDV- 2000  ............................................................................................................. 23 
2.2.2  Midazolam  ............................................................................................................. 24 
2.3 Benefit/Risk Assessment  ................................................................................................. 25 
2.3.1  Risk Assessment  .................................................................................................... 25 
2.3.2  Benefit Assessment  ............................................................................................... 26 
2.3.3  Overall Benefit -risk Conclusion  .............................................................................. 26 
3 OBJECTIVES AND ENDPOINTS  ................................................................................................ 27 
4 STUDY DESIGN  ....................................................................................................................... 28 
4.1 Overall Design  ................................................................................................................. 28 
4.2 Scientific Rationale for Study Design ............................................................................... 29 
4.3 Justification for Dose  ....................................................................................................... 29 
4.4 End of Study Definition  ................................................................................................... 29 
4.5 Protocol Deviations  ......................................................................................................... 30 
5 STUDY POPULATION  .............................................................................................................. 31 
5.1 Inclusion Criteria  ............................................................................................................. 31 
5.2 Exclusion Criteria  ............................................................................................................. 31 
5.3 Lifestyle Considerations  .................................................................................................. 33 
5.3.1  Meals and Dietary Restrictions  .............................................................................. 33 
5.3.2  Caffeine, Alcohol, and Tobacco  ............................................................................. 33 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 11 of 80 5.3.3  Activity ................................................................................................................... 34 
5.4 Screen Failures  ................................................................................................................ 34 
5.5 Early Discontinuation  ...................................................................................................... 34 
6 STUDY DRUG AND CONCOMITANT THERAPY  ........................................................................ 35 
6.1 Study Drug(s) Administered  ............................................................................................ 35 
6.2 Preparation, Handling, Storage, and Accountability  ........................................................ 36 
6.2.1  Drug Administration  .............................................................................................. 36 
6.2.2  Reporting Product Complaints  .............................................................................. 37 
6.3 Assignment to Study Intervention ................................................................................... 37 
6.4 Blinding/Masking ............................................................................................................ 38 
6.5 Study Drug Compliance  ................................................................................................... 38 
6.6 Dose Modification  ........................................................................................................... 38 
6.7 Treatment Access to Study Drug After the End of the Study  ........................................... 38 
6.8 Treatment of Study Drug Overdose  ................................................................................. 38 
6.9 Prior and Concomitant Therapy  ...................................................................................... 39 
6.9.1  Rescue Medicine  ................................................................................................... 39 
7 DISCONTINUATION OF STUDY DRUG, PARTICIPANT DISCONTINUATION/WITHDRAWAL AND 
STOPPING CRITERIA  .................................................................................................................... 40 
7.1 Discontinuation of Study Drug and Study Stopping Criteria  ............................................ 40 
7.1.1  Liver  Chemistry Stopping Criteria  .......................................................................... 40 
7.1.2  QTc Stopping Criteria  ............................................................................................. 40 
7.2 Participant  Discontinuation/Withdrawal From the Study  ............................................... 40 
7.3 Lost to Follow -up ............................................................................................................. 41 
8 STUDY ASSESSMENTS AND PROCEDURES  ............................................................................. 42 
8.1 Administrative  Procedures  .............................................................................................. 43 
8.1.1  Informed Consent Procedure  ................................................................................ 43 
8.1.2  Inclusion and Exclusion Criteria  ............................................................................. 43 
8.1.3  Medical History/Demography ............................................................................... 43 
8.1.4  Concomitant Medications  ..................................................................................... 43 
8.1.5  Check -in Criteria  .................................................................................................... 43 
8.2 Efficacy and/or Immunogenicity Assessments  ................................................................ 43 
8.3 Safety Assessments ......................................................................................................... 43 
8.3.1  Physical Examinations  ........................................................................................... 43 
8.3.2  Vital Signs  .............................................................................................................. 44 
8.3.3  Electrocardiograms  ................................................................................................ 44 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 12 of 80 8.3.4  Pulse Oxymetry  ..................................................................................................... 44 
8.3.5  Clinical Safety Laboratory Tests  ............................................................................. 45 
8.3.6  Pregnancy Testing  ................................................................................................. 45 
8.3.7  Suicidal Ideation and Behaviour Risk Monitoring  .................................................. 45 
8.3.8  Sedat ion VAS  ......................................................................................................... 46 
8.4 Adverse Events, Serious Adverse Events, and Other Safety Reporting  ............................ 46 
8.4.1  Time Period and Frequency for Collecting AE and SAE Information  ...................... 50 
8.4.2  Method of Detecting AEs and SAEs  ....................................................................... 50 
8.4.3  Reporting and Follow- up of AEs and SAEs  ............................................................. 50 
8.4.3.1  Reporting of SAEs  ............................................................................................................ 50 
8.4.3.2  Recording and Follow -up of AE and/or SAE  .................................................................... 51 
8.4.4  Regulatory Reporting Requirements for SAEs  ....................................................... 51 
8.4.5  Pregnancy .............................................................................................................. 52 
8.5 Pharmacokinetics  ............................................................................................................ 53 
8.6 Pharmacodynamics  ......................................................................................................... 53 
8.7 Genetics  .......................................................................................................................... 53 
8.8 Biomarkers  ...................................................................................................................... 53 
8.9 Health Economics  OR Medical Resource Utilisation and Health Economics  .................... 53 
9 STATISTICAL CONSIDERATIONS  ............................................................................................. 54 
9.1 Statistical Hypotheses ..................................................................................................... 54 
9.1.1  Multiplicity Adjustment  ......................................................................................... 54 
9.2 Analyses  Sets ................................................................................................................... 54 
9.3 Statistical Analyses  .......................................................................................................... 54 
9.3.1  General Considerations  ......................................................................................... 54 
9.3.2  Primary Endpoints Analysis  ................................................................................... 55 
9.3.3  Secondary Endpoints Analysis  ............................................................................... 55 
9.3.4  Tertiary/Exploratory Endpoints Analysis  ............................................................... 55 
9.4 Interim Analysis  ............................................................................................................... 55 
9.5 Sample  Size Determination  ............................................................................................. 55 
10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS  ............................. 56 
10.1  Appendix 1: Regulatory, Ethical, and Study Oversight Considerations  ...................... 56 
10.1.1  Regulatory and Ethical Considerations  .................................................................. 56 
10.1.2  Financial Disclosure  ............................................................................................... 56 
10.1.3  Informed Consent Process  ..................................................................................... 57 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 13 of 80 10.1.4  Data Protection  ..................................................................................................... 57 
10.1.5  Dissemination of Clinical Study Data  ..................................................................... 57 
10.1.6  Data Quality Assurance  ......................................................................................... 58 
10.1.7  Source Documents  ................................................................................................ 59 
10.1.8  Study and Site Start and Closure  ........................................................................... 59 
10.1.9  Publication Policy  .................................................................................................. 60 
10.2  Appendix 2: Clinical Laboratory Tests  ....................................................................... 61 
10.3  Appendix 3: Contraceptive Guidance and Collection of Pregnancy Information  ....... 63 
10.3.1  Definitions ............................................................................................................. 63 
10.3.2  Contraception Guidance  ........................................................................................ 63 
10.4  Appendix 4: Liver Safety: Suggested Actions and Follow- up Assessments ................ 64 
10.5  Appendix 5: Protocol Amendment History  ................................................................ 66 
10.6  Appendix 6: Pharmacokinetic Sampling Schedule  ..................................................... 67 
10.7  Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive  Vaccine Clinical Trials  .......................................................................................... 70 
10.8  REFERENCES  .............................................................................................................. 79 
 
TABLE OF TABLES  
Table 1  Objectives and Endpoints  .......................................................................................... 17 
Table 2  Study Drugs Administered......................................................................................... 35 
Table 3  Blood Volume during the Study  ................................................................................ 42 
Table 4  Populations for Analysis  ............................................................................................ 54 
Table 5  Protocol -required Safety Laboratory Tests  ............................................................... 62 
Table 6  PK sampling schedule  ................................................................................................ 67 
Table 7  List of Pharmacokinetic Parameters (non -exhaustive) .............................................. 68 
 
TABLE OF FIGURES  
Figure 1  Study Schema  ............................................................................................................ 19 
Figure 2  Schedule of Events (SoE)  ........................................................................................... 20 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 14 of 80 ABBREVIATIONS  
AE adverse event  
ALP alkaline phosphatase  
ALT aspartate aminotransferase  
AST alanine aminotransferase 
BID twice daily  
C-SSRS  Columbia- Suicide Severity Rating Scale  
CFR Code of Federal Regulations  
CNS central nervous system  
COVID -19 coronavirus disease 2019  
CRF/eCRF  Case Report Form/Electronic Case Report Form  
CYP cytochrome P450  
DDI drug- drug interaction  
DORA  dual orexin receptor antagonist  
ECG electrocardiogram  
EOS End of study  
FDA Food and Drug Administration  
FSH follicle -stimulating hormone  
GCP Good Clinical Practice  
GI gastrointestinal 
GMP  Good Manufacturing Practices  
GMR  Geometric mean ratio  
HBsAg  hepatitis B surface antigen 
HCl hydrochloride 
HIV human immunodeficiency virus  
IB Investigator’s Brochure  
ICF Informed Consent Form  
ICH International Council on Harmonisation 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 15 of 80 IEC Independent Ethics Committee  
IgM immunoglobulin M  
IND investigational new drug  
INR International normalised ratio  
IRB Institutional Review Board 
IV intravenous 
  
OUD  opioid use disorder  
OX1R/OX2R  orexin -1/orexin -2 receptor  
PK Pharmacokinetic (s) 
QTcF  heart rate -corrected QT interval  
SAE serious adverse event  
SAP statistical analysis plan  
SUSAR  suspected unexpected serious adverse reaction  
TEAE  treatment emergent adverse event  
ULN  upper limit of normal  
VAS visual analogue scale  
WONCBP Women of nonchilbearing potential  
 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 16 of 80 1 PROTOCOL SUMMARY  
1.1 Synopsis  
Protocol Title:  
An Open Label, Fixed -sequence Study to Evaluate the Potential CYP3A4 Induction E ffect of 
INDV- 2000 using Oral Midazolam as a Probe in Healthy Adults Participants  
Short Title:  
Study of potential CYP3A4 induction by INDV -2000 in healthy adults  
Regulatory Agency Identifier Number(s):  
Registry  Identifying  Number  
IND 145881  
Rationale:  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 17 of 80 Objectives and Endpoints  
Table 1 Objectives and Endpoints  
Objective Endpoint  
Primary   
• To determine changes in primary 
pharmacokinetic ( PK) parameters 
(maximal and overall plasma exposure) of 
midazolam and 1 -hydroxymidazolam 
following repeated  oral doses of 
INDV -2000  • Cmax , AUC 0-∞, and AUC last of midazolam and 
1-hydroxymidazolam following dosing of 
midazolam on Day 1 and dosing of midazolam + INDV -2000 on Day 15  
Secondary   
• To assess the safety and tolerability of 
repeated oral doses of INDV -2000  alone 
and in combination with midazolam as  
determined by adverse event (AE) 
reporting  • Safety and tolerability of INDV -2000 as 
determined by AE reporting (incidence,  
seriousness,  severity , and relatedness of 
treatment emergent adverse events 
[TEAEs ]) 
Tertiary/Exploratory   
Overall D
esign  Synop sis: 
This is an open label, single -centre , fixed -sequence study in healthy adult participants.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 18 of 80 Brief Summary:  
The purpose of this study is to evaluate the CYP3A induction potential of INDV -2000 using 
midazolam as a sensitive substrate .  
Participants who meet the eligibility criteria will be admitted to the study site on Day - 1, and 
will remain confined until after the 24 -hour blood draw and/or study procedures on Day  16. 
On Day 1, participants will receive a single oral dose of midazolam syrup . On Day s 2-15, 
participants will receive  INDV- 2000 BID  with a single oral dose of midazolam syrup 
co-administered on Day 15.  
Particip
ants who received all doses of study drug s will return to the study site 7± 2 days after 
the last dose  for end of study (EOS)  procedures, and to determine if any AE has occurred since 
the last study visit.  Participants who terminate the study early will be asked to complete EOS 
procedures at the time of early termination in place of an EOS visit. Participants will be 
encouraged to stay up to 24 hours after the last dose to complete early termination assessments. 
Number of Participants:  
Approximately 20 participants will be assigned to receive the study drug s. This sample size is 
based on earlier clinical experience and is expected to provide at least 16 evaluable 
participants,  
  
Note : A participant will be considered enrolled at the time he/she receives the first dose of 
study drug . 
Study Treatment  and Duration:  
On Day 1, p articipants will receive a single oral dose  of 5 mg  midazolam.  
On Days 2 -15, participants will receive  INDV -2000 BID (approximately 
every 12 hours) with a single oral dose of 5 mg  midazolam co-administered with the morning 
INDV- 2000 dose on Day  15. 
The total planned study duration (screening to EOS) for each participant will be approximately 
7 weeks. This includes a screening period of up to 4 weeks (ie within 28 days prior to dosing on 
Day 1) , a treatment period of approximately 2  weeks (Days 1 to 16) , and a n EOS visit  
approximately 1 week from last dose (7 ±2 days) .  
Data Monitoring/Other Committee: No  
 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 20 of 80 1.3 Schedule of Events (SoE)  
Figure 2 Schedule of Events (SoE)  
Study Procedure s 1 Screening 2 Treatment Period (Days) 
EOS/ET 
-1 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Informed consent  X                   
Inclusion and exclusion 
criteria  X X                  
Demography  X                   
Medical history  X                   
Full physical 
examination including 
height and weight  5 X X                X X 4 
Testicular examination 
(males only) 6 X                 X X 4 
COVID -19 screen   X                  
HIV, Hepatitis B, and 
Hepatitis  C (antibody)   X                   
Drug and alcohol 
screen  X X                 X 4 
Serum pregnancy test 
(females  only)  X                   
Urine pregnancy test 
(females only)   X                X X 4 
Serum FSH (PMP 
(females only)  X                   
Haematology, serum 
chemistry 7, urinalysis  X X  X 8  X 8    X 8    X 8   X 8 X X 4 
Coagulation X   X 8      X 8        X X 4 
12-Lead ECG  X  X 9 X 9 X 9 X 9 X 9   X 9 X 9   X 9 X 9  X 9 X X 4 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 21 of 80 Study Procedure s 1 Screening 2 Treatment Period (Days) 
EOS/ET 
-1 3 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 
Vital signs  X  X 10 X 10 X 10 X 10 X 10   X 10 X 10   X 10 X 10  X 10 X X 4 
C-SSRS 11 X X        X       X  X 4 
Sedation VAS    X 12 X 13  X 13    X 13    X 13   X 12 X X 4 
Pulse oximetry 14   X              X   
AE review   X X X X X X X X X X X X X X X X X X 4 
Concomitant 
medication review  X X X X X X X X X X X X X X X X X X X 4 
INDV- 2000 dosing 15    X X X X X X X X X X X X X X   
Midazolam dosing    X              X   
PK Sampling  16   X X      X  X     X X  
 
AE=adverse event; C-SSRS= Columbia suicide severity rating scale ; COVID -19= Coronavirus disease 2019 ; ECG=electrocardiogram; ET=early termination; 
EOS=End of study;  FSH= follicle stimulating hormone ; HIV=Human immunodeficiency ; PK=pharmacokinetic; PMP= postmenoposal ; VAS= Visual Analogue Scale ;  
 
1. For details on Procedures, refer to Section 8. 
2. Within 28 days before Day 1  dosing. 
3. Participants will be admitted to the study site on Day - 1, at the time indicated by the study site, and will remain confined until 
after the 24 -hour blood draw and/or study procedures on Day  16. Participants may be admitted earlier than Day - 1 for COVID -19 
testing not related to study protocol as per study site requirements.  
4. Participants who received all dose s of study drug s will return to the study site 7±2 days after the last dose for EOS  procedures, 
and to determine if any AE has occurred since the last study visit. Participants who terminate the study early will be asked to 
complete EOS procedure s at the time of early termination  in place of an EOS visit. Participants will be encouraged to stay up to 
24 hours  after the last dose  to complete early termin ation assessments.  
5. Height collected at screening only.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 22 of 80 6. For male participants, a testicular/epididymal exam ination will be performed at sc reening , on Day 16,  and at EOS Visit (7±2 days 
following last dosing ) or early termination . Any clinically significant change from screening will be reported as an AE .  
7. Samples for serum chemistry will be obtained after a fast of at least 12 hours, however, in case of dropouts or rechecks, 
participants may not have fasted for 12 hours prior to when the serum ch emistry sample is taken .  
8. To be performed prior to morning dosing.  
9. On Days 1, 2, 4, 8, 12, and 15, 12 -lead ECG will be collected within 2 hours prior to morning dose  (predose ) and at 1  hour 
(±20 min), 2 hours (± 20 min), and 4 hours ( ±20 min ) post morning dose ; on Days 3, 5, 9, and 13, 12- lead ECG will be collected 
within 2 hours prior to morning dose (predose); on Day 16, the 12- lead ECG will be collected at 24 hours post Day 15 morning 
dose ( ±20 min ).  
10. On Days 1, 2, 4, 8, 12, and 15, vital signs will be co llected within 2 hours prior to morning dose ( predose ) and at 1 hour ( ±15 min ), 
2 hours (± 15 min), and 4 hours ( ±15 min ) post morning dose ; on Days 3, 5, 9, and 13, vital signs  will be collected within 2 hours 
prior to morning dose (predose); on Day 16, the vital signs will be collected at 24 hours post Day 15 morning dose ( ±20 min ). 
11. Baseline/Screening C -SSRS version (lifetime history and past 6 months) will be completed at screening , the Since last Visit C -SSRS 
version will be completed at all other time points . On Day 8 and Day 15, C-SSRS will be collected at 6 hour s (±1 hour) post 
morning  dose.  
12. Sedation VAS will be collected within 1 hour prior to morning dosing ( predose ) and at 30 min  (±5 min ), 1 hour  (±10 min) and 
2 hours ( ±10 min) post morning dose .  
13. Sedation VAS will be collected  within 1 hour  prior to morning dosing ( predose ) and at 2 hours ( ±10 min) post morning  dose.  
14. Baseline pulse oximetry will be performed  within 1 hour prior to morning dosing; pulse oximetry  will be monitored continuously 
with a pulse oximeter for approximately 6 hours post- dose, with readings recorded 2  hours, 4 hours, and 6 ho urs post -dose 
(±10 min). 
15. INDV- 2000 will be administered BID  (ie, approximately every 12 hours). 
16. For PK collection time  points, please refer to  Section 10.6 (appendix). 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 23 of 80 2 INTRODUCTION  
INDV- 2000 ( also referred to as C4X_3256) is a highly potent and selective OX1R  antagonist that 
is being developed as a therapy for the treatment of OUD.   
2.1 Study Rationale  
2.2 Backg
round 
2.2.1 INDV -2000 
INDV- 2000 is a potent  and competitive antagonist of  the human OX1 R with good selectivity in 
vitro. In humans, the OX1 R is expressed in the brain, predominantly in projections from the 
lateral hypothalamus, including the ventral tegmental area and the  ventromedial prefrontal 
cortex and it binds the neuropeptide Orexin- A and, with less affinity, Orexin -B. The number of 
Orexin -A producing neurons is increased in the brains of individuals with heroin dependence 
(Thannickal 2018). Antagonism of the OX1 R inhibits addiction- related behaviours in nonclinical 
rodent models including self- administration, relapse to drug  seeking, and withdrawal ( Azizi 
2010,  Mahler 2012,  Hooshmand 2017, Dunn 2019 ). Hence it is hypothesised that OX1 R 
antagonists should show clinical benefit in the  treatment of substance use disorders, including 
OUD, by reducing craving, relapse , and symptoms of withdrawal.  
There ar e several selective  OX1R antagonists (eg, ACT -539313, JNJ -61393215, AZD4041) and 
dual OX1R/OX2R antagonists already in clinical development.  BELSOMRA® (suvorexant) and 
DAYVIGO® (lemborexant) are dual OX1R/OX2R  antagonists approved for  the treatment of 
insomnia ( Coleman 2017, Murphy 2017 ). There have been no published reports of any 
significant safety issues in animals or humans with these compounds.  
The most relevant data  on INDV -2000  for the present study are summari sed below. A detailed 
description of the chemistry, pharmacology, efficacy, and safety of INDV- 2000 is provided in the 
most recent Investigator’s Brochure ( IB) and IB supplement.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 25 of 80 oral doses of 0.25 to 1 mg/kg. Midazolam is primarily metabolis ed in the gut and liver by 
CYP3A4 to its pharmacologic active metabolite , 1-hydroxymidazolam, followed by 
glucuronidation. The active metabolite, 1- hydroxymidazolam , is equipotent and equally 
effective as unchanged midazolam on a total plasma concentration basis. Midazolam is also 
metabolis ed to 2 other minor metabolites (about 4% of the dose). The mean elimination T 1/2 of 
midazolam ranges from 2.2 to 6.8 hours. After oral or intravenous (IV) administration, 63% to 
80% of midazolam is recovered in urine as 1- hydroxymidazolam glucuronide. 
The most frequently reported AEs following midazolam administration include emesis (8%) and 
nausea (4%). Midazolam HCl syrup has also been associated with reports of respiratory 
depression, airway obstruction, desaturation, hypoxia, and apnea, most often when used concomitantly with other CNS depressants.  
Refer to the full prescribing information for a more detailed background on midazolam 
(Midazolam HCl Syrup, 20 21). 
2.3 Benefit/Risk Assessment  
Benefit and risk assessment are highli ghted below; however m ore detailed information about 
the known and expected benefits and risks and re asonably expected AEs of  INDV- 2000 and 
midazolam may be found in the  IB and IB supplement and in the presc ribing information  
(Midazola m HCl Syrup, 2021) , respectively.  
2.3.1 Risk Assessment  
Investigational Study Drug :  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 26 of 80 Study Procedures :  
A potential risk associated with study procedures are the risks associated with phlebotomy 
since multiple blood samples are collected throughout the study period. However, limits for 
number of samples and sample volumes are in place, according to local guidance.  
Other Study Medication (Midazolam ):  
Midazolam is associated with reports  of respiratory depression, airway obstruction, 
desaturation, hypoxia, and apnea, although most often when used concomitantly with other 
CNS depressants . An oral dose of  midazolam (0.1 mg/kg) affect s peak saccadic velocity of eye 
movement, postural sway area, critical flicker fusion frequency, and mental sedation as measured on a VAS ( Misaka 2011) . To minimis e the risk of AE occurrence, a  lower dose (5 mg) 
than that typically required for effective sedation (0.5 mg/kg to a maximum dose of 20  mg) 
according to the dosing recommendations found in the full prescribing information for midazolam will be administered  to ensure a safety margin while allowing robust PK assessment . 
In addition, as both study drugs may induce somnolence, mental sedation as measured on a VAS will be evaluated throughout the study.  Also, oxygen level (oxygen saturation) in  the blood 
will be measured via pulse oximetry in every participants for the 6 hours following each midazolam dosing.  
Rescue med ication will also be available as needed.  
2.3.2 Benefit Assessment  
Participants in this clinical study will not receive direct health benefits from study drug during 
participation. An indirect health benefit to the participants enrolled in this study is the free 
medical tests received at screening and during the study.  
2.3.3 Overall Benefit -risk Conclusion  
This is a study in healthy participants, and there is no direct benefit to study participants. The data obtained from this healthy participant study may inform future clinical studies in 
participants with OUD  or other indications under study.  
Administratio n  BID for 14 days  is not expected to cause any safety concern in healthy 
participants. The dose of midazolam administered in this study is also not anticipated to induce 
any potential risk to participants taking part  in this study, as it is a single dose administered at a 
lower dose than typically required for effective sedation according to the dosing 
recommendations found in the full prescribing information for midazolam.  
The study site  will follow coronavirus plan to minimis e the exposure of participants to 
coronavirus disease 2019 ( COVID -19). The Institutional Review Board  (IRB)/Independent Ethics 
Committee  (IEC) approved COVID- 19 clinical pharmacology unit management plan will be 
provided separately.  
The safety monitoring practices employed by this protocol (ie, AEs, clinical laboratory tests, vital sign measurements, pulse oximetry, 12 -lead ECG, sedation VAS, C- SSRS, and physical 
examination) are adequate to protect the participants ’ safety and should detect all expected 
TEAEs.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 27 of 80 3 OBJECTIVES  AND  ENDPOINTS  
 
Objective Endpoint  
Primary   
• To determine changes in primary PK 
parameters (maximal and overall plasma 
exposure) of midazolam and 
1-hydroxymidazolam following repeated 
oral doses of INDV -2000  • Cmax, AUC 0-∞, and AUC last of midazolam 
and 1 -hydroxymidazolam following 
dosing of midazolam on Day 1 and dosing of midazolam + INDV -2000 on Day 15  
Secondary   
• To assess the safety and tolerability of 
repeated oral doses of INDV -2000  alone 
and in combination with midazolam as  
deter mined by AE reporting  • Safety and tolerability of INDV -2000 as 
determined by AE reporting (incidence,  
seriousness,  severity , and relatedness of 
TEAEs)  
Tertiary/Exploratory   

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 28 of 80 4 STUDY DESIGN  
4.1 Overall Design  
• This is an open label, single -cent re, fixed -sequence study in healthy adult 
participants. 
• Approximately 20 males and females of non -child bearing potential participants will 
be enrolled to provide at least 16 evaluable participants . 
• The tota l planned study duration (screening to EOS) for each participant is 
approximately 7 weeks . This includes  a screening  period, a treatment period, and an 
EOS visit: 
o Screening: Day -28 up to dosing on Day 1;  
o Treatment Period:  Day 1 to Day 16  
 Day - 1: Check -in at the time indicated by the study site, for eligible 
participants. Participants may be admitted earlier than Day -1 for 
COVID -19 testing not related to study protocol as per  study site  
requirements . 
 Day 1: Participants will receive a single oral dose of midazolam. 
 Days 2 to 15: Participants will receive oral doses of INDV- 2000 BID . 
 Day 15: Participants will receive a single oral dose of midazolam 
co-administered with INDV -2000 morning dose . 
 Day 16: Check -out from the study site following completion of the 
24-hour blood draw and/or study procedures scheduled on that day ; 
note that the study site may decide to confine the participants for longer 
periods at the I nvestigator’s discretion.  
o EOS Visit:  Participants w ho received all dose s of study drug s will return to the 
study site 7 ±2 days after the last dose for EOS procedures, and to determine if 
any AE has occurred since the last study visit . Participants who terminate the 
study early will be asked to complete  EOS procedures at the time of early 
termination  in place of an EOS visit  and will be encouraged to stay up to 24 hours  
after the last dose  to complete early termination assessments.  
• Blood sampling for midazolam and 1 -hydroxymidazolam plasma concentrations will 
be conducted for 24 hours on Day 1 and Day 15.  
• Safe
ty will be monitored throughout the study by AE  review , clinical laboratory tests, 
vital sign measurements, pulse oximetry, ECG parameters, C- SSRS, sedation VAS, and 
physical examination.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 29 of 80 4.2 Scientific Rationale for Study Design  
This clinical study will e valuate the potential effect of INDV- 2000 on the activity of CYP3A , 
thereby provid ing information on whether CYP3A substrate drug s can be co -administered safely 
with INDV- 2000,  and if there is a need for focused clinical DDI studies (eg, oral contraceptive  
studies) . Midazolam is considered a sensitive index substrate of CYP3A4 as per the Food and 
Drug Administration ’s (FDA’s ) web site for Drug Development and Drug  Interactions ( FDA 2022) 
and was thus selected as a probe for this study . Although the syrup formulation is indicated for 
use in pa ediatric patients, it was selected over the IV formulation  as it allows to assess the 
intestinal CYP3A activity  and is routinely used in the adult population and commonly selected 
for DDI studies .  
The study is designed as an open label, fixed -sequence study for the following reasons:  
• Since the primary endpoint is an objective  measurement, there is no risk of potenti al 
bias of the study results; hence, neither study blinding  nor inclusion of a placebo 
group is required , and the study can be conducted as open label. 
• A fixed -sequence allows to prevent any carryover effect of INDV -2000 on CYP3A 
activity due to INDV -2000 potential inductive effect while providing the advantage of 
reducing the study variability since participants act as their own control . 
Since the purpose of the study is to validate the potential of INDV- 2000 to perpetrate induction, 
and as it may take about 2 weeks of daily administration to achieve maximum level of induction 
for a perpetrator, INDV- 2000 will be administered for 14 days (Day 2 to Day 15)  with the 
substrate being co -administered on Day  15. 
Oral administration of midazolam has demonstrated linear PK and thus will be given as a single dose.  
Based on the short half- life of midazolam and 1 -hydroxymidazolam, PK sampling for a duration 
of 24 hou rs should be adequate to ensure robust characterization of total exposure of the 
analyte s. Blood samples for INDV -2000 will be collected to confirm expected plasma 
conce ntrations.  
4.3 Justification for Dose  
4.4 End of S
tudy Definition  
The end of the study is defined as the EOS visit (Day 22±2  days).  
A participant is considered to have completed the study if the participant has completed 
dosing, did not discontinue or terminate the study early, and has completed most of the scheduled procedures including the EOS visit (Day 22±2  day). 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 30 of 80 4.5 Protocol Deviations  
A protocol deviation is any noncompliance with the clinical study protocol or ICH/GCP 
requirements. The noncompliance may be either on the part of the participant, the Investigator, or the study -site staff. It is the responsibility of the I nvestigator and study -site staff 
to use continuous vigilance to identify and report deviations to Indivior or specified designee, and to the IRB/ IEC per local requirements.  
  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 31 of 80 5 STUDY POPULATION  
Prospective approval of protocol deviations to recruitment and enrolment criteria, also known 
as protocol waivers or exemptions, is not permitted.  
5.1 Inclusion Criteria  
Participants are eligible to be included in the study only if all of the following criteria apply:  
1. Participant must be  18 to 55 years of age inclusive, at the time of signing the 
informed consent.  
2. Body weight of a minimum of 50.0 kg at the S creening Visit and body mass index 
within the range 18.0 – 32.0 kg/m2 (inclusive).  
3. Male or female who is healthy  as determined by medical evalu ation.  
4. Female s will be of non- childbearing potential. Females of non -childbearing potential 
are considered women who : 
• Do not have a uterus, or  
• Are surgically sterile (e g, has undergone complete hysterectomy, bilateral 
oophorectomy, hysteroscopic steriliza tion, or tubal ligation), or  
• Have permanent cessation of ovarian function due to ovarian failure or surgical removal of the ovaries, or  
• Are post -menopausal as defined by 12 months or more of spontaneous 
amenorrhea as confirmed by a follicle -stimulating hormone (FSH) >30 mIU/mL  
5. Male participants agree to follow contraception guidelines in Section  10.3 
(appendix). 
6. Continuous non- smoker who has not used nicotine - and tobacco -containing 
products for at least 3  months prior to the first dosing based on participant 
self-reporting . 
7. Capable of giving signed informed consent as described in Section  10.1.3 (appendix) 
which includes compliance with the requirements and restrictions listed in the Informed Consent Form ( ICF) and in this protocol . 
5.2 Exclusion Criteria  
Participants are excluded from the study if any of the following criteria apply:  
1. Have an ongoing medical history of clinically significant neurological, cardiovascular, 
renal, hepatic, chronic respiratory or GI  disease, psychiatric or other disorder as 
judged by an I nvestigator that could potentially affect the study outcomes or 
compromise participant safety.  
2. Have clinically significant abnormal biochemistry, haematology or urinalysis results 
as judged by an Inve stigator . 
3. Have a history of narcolepsy or sleep apnea . 
4. Have disorders that may interfere with drug absorption, distribution, metabolism 
and excretion processes . 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 32 of 80 5. Current active hepatic or biliary disease.  
6. Participants with cholecystectomy <90 days prior to screening.  
7. Positive test results for human immunodeficiency virus (HIV) -1/HIV -2 antibodies, 
Hepatitis B surface a ntigen (HBsAg) or Hepatitis C antibodies. 
8. Have a blood pressure reading outside of the following range: Systolic <86 or 
>149 mmHg; Diastolic <50 or >94 mmHg  
9. Serious cardiac illness or other medical condition including, but not limited to:  
• Uncontrolled arrhythmias  
• History of congestive heart failure  
• QTcF >450 msec for males and >470 msec for females or history of prolonged QT syndrome   
• Myocardial infarction  
• Uncontrolled symptomatic angina  
10. History of suicidal ideation within 30 days prior to providing written informed consent as evidenced by answering "yes' to questions 4 or 5 on the suicidal ideation portion of the C -SSRS completed at th e Screening Visit or history of a suicide 
attempt (per the C -SSRS) in the 6 months prior to informed consent.  
11. Healthy participants  who are taking, or have taken, any prescribed or 
over -the- counter drugs (other than 2 g rams  of acetaminophen per 24-hour period as 
of Day 1, hormone replacement therapy , or thyroid hormone replacement therapy 
[see Section  6.9]) or herbal remedies in the 14 days or 5 half -lives (whichever is 
longer) prior to first dose of study drug .  
12. Treatment with any known drugs that are moderate or strong inhibitors/inducers of CYP3A4 or CYP2C19, including St. John’s Wort, within 30 days prior to first dose of 
study drug.  
13. Any consumption of food or drink containing poppy seeds, grapefruit or Sevill e 
oranges within 14 days prior to the first dose of study drug.  
14. Regular alcohol consumption in males >21 units per week and females >14 units per week (1 unit = ½ pint beer, 25 mL of 40% spirit or a 125 mL glass of wine).  
15. Positive test result for alcohol and/or drugs of abuse at screening or at check- in. 
16. Female participant with a positive pregnancy test at the Screening V isit or at first  
check -in or who are lactating.  
17. Concurrent treatment or treatment with an investigational drug or device within 
30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug.  
18. Blood donation of approximately 500 mL or more within 56 days or plasma donation within 7 days of screening.  
19. Known hypersensitivity to INDV -2000 or any other ingredient in the INDV -2000 
formulation. 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 33 of 80 20. Known hypersensitivity to midazolam or any other ingredient in midazolam HCl 
syrup. 
21. Site staff and/or participants who have a financial interest in, or an immediate family member of either the site staff and/or Indivior employees, directly involved in the 
study. 
22. Major surgical procedure (as defined by the I nvestigator) within 90 days prior to the 
first dose of study drug or still recovering from prior surgery.  
23. Concurrent enrolment in another clinical study, unless it is an observational study.  
24. Participants who are unable, in the opinion of the I nvestigator, to comply fully with 
the study requirements.  
25. Any condition that, in the opinion of the I nvestigator or Indivior , would interfere 
with evaluation of the study drug or interpretation of participant safety or study 
results.  
5.3 Lifestyle Considerations  
5.3.1 Meals and Dietary Restrictions 
1. No water (except water provided with dosing) is allowed from 1 hour prior to and until 1 hour after each dosing of study drug , but will be allowed ad libitum at all 
other times.  
2. On all PK days (Day 1 and Day 15 ), participants will fast overnight for at least 
10 hours before and at least 4 hours after each morning dose of study drug . For all 
other dosing, participants will fast for at least 2 hour before and at least  2 hours 
after dosing of study drug . 
3. On all days that participants are confined in the study site, meals and/or snacks will be provided at appropriate times. Each meal and/or snack served at the study site will be standardi sed and will be  similar in caloric content and composition. 
Participants will not be required to fully consume any meal or snack.  
4. Refrain from consumption of food or drink containing poppy seeds, grapefruit or Seville oranges from 14 days before the first dosing  of study drug until after 
collection of the final PK sample.  
5. Participants should be instructed to fast for at least 12 hours before collection of 
fasting clinical laboratory assessment samples as indicated in Section  10.2 
(appendix). 
5.3.2 Caffeine, Alcohol , and Tobacco  
1. Participants will be instructed to abstain from ingesting caffeine - or xanthine -
containing products ( eg, coffee, tea, cola drinks, and chocolate) for  24 hours  prior to 
the first dose of study drug  until after collection of the final PK sample.  
Small amounts of caffeine derived from normal foodstuffs (eg, 250 mL/8 oz/1 cup decaffeinated coffee or other decaffeinated beverage, per day, with the exceptio n of 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 34 of 80 espresso; 45 g/1.5 oz chocolate bar per day) would not be considered a deviation to 
this restriction. 
2. Participants will be instructed to abstain from alcohol for 48 hours prior to the first 
dose of study drug  until after collection of the final PK sam ple. 
3. Participant will abstain from use  of nicotine- or tobacco- products from 3 months  
before the first dosing and through confinement. 
5.3.3 Activity  
1. Participants will remain seated for the first 4 hours post  morning dose  and the first 
2 hours post evening dose, except when they are supine or semi reclined for study 
procedures. Participants  will then resume normal activity.  During the first 4 hours  
post  morning dose  or 2 hours post evening dose , participants may be allowed  to rise 
for brief periods under supervision ( eg, in order to use the toilet facilities).  
2. Should AEs occur at any time, participants may be placed in an appropriate position or will be permitted to lie down on their right side.  
3. Participants  will be instructed to refrain from strenuous physical activity which could 
cause muscle aches or injury, including contact sports at any time from the Screening V isit until completion of the study.  
5.4 Screen Failures  
See Section  9.2 for definition of enrolled participant.  
A screen failure occurs when a  participant who has consent ed to participate in the clinical study 
is not subsequently entered in the study . A minimal set of screen failure information is required 
to ensure transparent reporting of screen failure participants to meet the Consolidated Standards of Reporting Trials publishing requirements and to respond to queries from regulatory authorities. Minimal information includes demography, screen failure details ( eg, 
reason for screen failure, such as not eligible, with drew consent, AE), eligibility criteria, and any 
SAE.  
Individuals who do not meet the criteria for participation in this study (screen failure) due to a reason that is expected to resolve or has resolved, may be rescreened based on discus sion and 
agreement  between the Investigator and the medical monitor. 
5.5 Early Discontinuation  
A participant will be considered an early discontinuer if the participant received study drug and 
did not complete all visits. Reasons for not completing all visits will be captured in the 
participant source documents and the Case Report Form ( CRF).  
The definition of a study completer is provided in Section  4.4.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 35 of 80 6 STUDY DRUG  AND CONCOMITANT THERAPY  
Study drug is defined as any investigational drug(s), marketed product(s), placebo or medical 
device(s) intended to be administered to a study participant according to the study protocol.  
6.1 Study Drug(s) Administered 
 
Table 2 Study Drugs Administered 
Drug Name  INDV -2000  Midazolam HCl  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 36 of 80 6.2 Preparation, Handling , Storage , and Accountability  
1. The I nvestigator or designee must confirm appropriate temperature conditions have 
been maintained during transit for all study drug received and any discrepancies are 
reported and resolved before use of the study drug  as per the pharmacy man ual. 
2. Only participan ts enrolled in the study may receive study drug and only authorised 
site staff may supply or administer study drug. The dispensing of study drug to the participant must be documented on the drug dispensing form. All study drug dispensation will be performed by a pharmacist or designee, checked by a study centre staff member and documented on a drug dispensation form. Refer to the pharmacy manual for further details.  
3. All study drug must be stored in a secure, environmentally controlled, and 
monitored (manual or automated) area in accordance with the labelled storage 
conditions with access limited to the I nvestigator and authorised site staff.  
4. The I nvestigator, institution, or the head of the medical institution (where 
applicable)  is responsible for study drug accountability, reconciliation, and record 
maintenance ( ie, receipt, reconciliation , and final disposition records).  
5. Participant level dispensation of study drug must be documented on the appropriate participant level account ability form. All study drug dispensation will be performed 
by a pharmacist or designee, checked by a study -site staff member and documented 
on a drug dispensation form.  
6. Used and unused study drug must be available for verification by the site monitor during on -site monitoring visits.  
7. Further guidance and information for the final disposition of unused study  drugs are 
provided in the  pharmacy manual.  
8. Upon completion of the study and/or as requested by Indivior , copies of study drug 
accountability records will be provided to Indivior  or designee.  
6.2.1 Drug Administration 
When participants are dosed at the site, they will receive the study drug (s) directly from the 
Investigator or designee, under medical supervision.  
A record of the number of INDV -2000 capsules dispensed to and taken by each participant must 
be maintained and reconciled with study drug and compliance records. Study drug administration date and time will be recorded in the CRF  (See Section 6.5). 
Treatment  is as follows:  
o Midazolam 5 mg (2.5 m L of 2 mg/mL syrup) on Day 1  
o INDV- 2000  BID on Day 2 to Day 15 with midazolam 
5 mg (2.5 m L of 2 mg/mL syrup) co -administered on the morning of Day 15 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 37 of 80 • Following initial INDV -2000 morning dosing on Day 2, each subsequent INDV -2000 
morning do se will be adminis tered within 1 hour before or after the dosing time 
established on Day 2. For each evening dose, INDV -2000 will be administered 
approximately 12 hours after the morning dose on that da y. 
• The pharmacy at the study site  will provide each dose in individual u nit dose containers 
for each participant, as appropriate.  When the individual dose for a  participant is 
prepared from a bulk supply, the preparation of the dose will be confirmed by a second 
member of the study -site staff.  
• Study drugs will be administered under fasted conditions with approximately  240 mL of 
water (see Section 5.3.1). 
• Participants will be instructed not to crush, split, or chew the capsul es. 
• The exact clock time of dosing will be recorded.  
• Dosing compliance will be monitored as described in Section 6.5. 
6.2.2 Reporting Product Complaints  
The I nvestigator and study -site staff are responsible for prompt recognition and reporting of 
product quality complaints to Indivior   within 1 business day of 
identifying the issue .  
A product complaint is any concern pertaining to the manufacturing or quality control of the study drug and includes, but is not limited to broken capsules, labelling defects, packaging 
defects, or study drug that is thought to be ineffe ctive, or has an appearance, taste , or odour 
that is outside of what is expected.  
See the pharmacy manual for further details.  
The following information should be provided:  
• study number  
• site contact/reported by  
• participant number (if already assigned to a participant)  
• description of issue  
• picture, if available (photographs should be taken only if safe to do so/within site policy or 
practice to take photograph)  
Retain the product and packaging in quarantine for further investigation, as required.  
6.3 Assignment to Study Intervention 
The I nvestigator is responsible for maintaining a master list ( ie, a participant identification list) 
of all consented participants and will document all participants that did not meet study eligibility criteria ( ie, screen  failures), including reason(s) for ineligibility ( ie, a participant 
screening and enrolment log).  
Each parti cipant will be assigned a unique identification number upon the S creening Visit. 
Participants  who complete the study screening assessments and meet all the eligibility criteria 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 38 of 80 will be assigned a unique identification number at the time of the first dosing, different from 
the screening number, and will receive the corresponding product.  
All participants will receive each treatment in a sequential ma nner.  
6.4 Blinding /Masking 
This is an open label study. There is no randomization in this study.  
6.5 Study  Drug Compliance  
A qualified designee will be responsible for monitoring the administration of the timed oral  
doses. The date and time of each dose administered will be recorded in the source documents and recorded in the CRF. A mouth check will be performed by the qualified designee to ensure 
that the participants have swallowed the study drug. Once a participant has finished the dosing 
water, the qualified designee will use a flashlight and a tongue depressor to check the 
participant’s  mouth. Participants ’ hands will also be verified to ensure that the study drug was 
ingested.  
Any deviation(s) from the prescribed dosage regimen will be recorded in t he electronic (e) CRF.  
The time of dos ing is defined as the time the participant has swallowed the study drug  and the 
qualified designee has completed check of oral cavity and hands.  
The exact clock time of dosing will be recorded. 
6.6 Dose Modification  
The dose and administration of the study drugs  to any participant may not be modified. 
6.7 Treatment Access  to Study Drug After the End of the Study  
Not applicable.  
6.8 Treatment of Study  Drug Overdose 
For this study, any dose of study drug greater than that specified in the protocol will be 
considered an overdose. In the event of overdose, general supportive measures and close 
monitoring are recommended.   
Overdoses are medication errors that are not considered AEs unless there is an untowar d 
medical occurrence resulting from the overdose.  
In the event of a n overdose, the I nvestigator should do the following : 
1. Evaluate the participant to determine, in consultation with the medical monitor, if possible, whether study drug should be interrupted or whether the dose should be 
reduced. 
2. Closely monitor the participant for any AE/SAE and laboratory abnormalities.  
3. Obtain a plasma sample (for INDV -2000 or midazolam and 1- hydroxymidazolam ) for PK 
analysis within 24 hours  from the time  of the last dose of study drug if requested by the 
medical monitor (determined on a case -by-case basis).  
4. Document the quantity of the excess dose as well as the duration of the overdose.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 39 of 80 6.9 Prior and Concomitant Therapy  
Any medication ( including prescription and non pres cription medications, vitamins and dietary 
or herbal supplements) that the participant is receiving during the study must be recorded 
along with the following : 
• Reason for use  
• Dates of administration including start and end dates  
• Dosage information including dose and frequency  
The medical monitor should be contacted if there are any questions regarding concomitant or prior therapy.  
Participants must not have received concurrent treatment or treatment with investigational 
drug or device within 5 half- lives (if known) of the investigational agent or 30 days prior to the 
first dose of study drug , whichever is longer.  
Participants must abstain from taking any prescribed or over -the- counter drugs or herbal 
remedies within 14 days or 5 half- lives (whichever is longer) prior to first dose of study drug  
until completion of the 7± 2 days EOS  Visit. Hormone replacement therapy  and thyroid hormone 
replacement  therapy , if the participant  has been on the same stable dose for at least 3 months 
prior to the first dosing, will also be allowed . After first dosing of study drug, a cetaminophen, at 
doses of  up to  2 grams/24 hours, is permitted for use at the discretion of the Investigator or 
designee .  
Moderate or strong inhibitors/ inducers of CYP3A4 or CYP2C19, including St. John’s Wort, will be 
prohibited within 30 days prior to first dose of study drug  until completion of the 7±2 days EOS  
Visit. Appropriate sources (eg, Flockhart Table ™) will be consulted to confirm lack of 
PK/pharmacodynamic  interaction with the study drug(s).  
6.9.1 Rescue Medicine 
For severe AEs, including any midazolam- related events such as respiratory depression and 
oxygen desaturation, standard contents of the emergency crash cart available at the study site (eg, oxygen, flumazenil) will be used as rescue medication at the discretion of the Investigator 
or designee.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 40 of 80 7 DISCONTINUATION OF STUDY DRUG , PARTICIPANT 
DISCONTINUATION/WITHDRAWAL  AND STOPPING CRITERIA  
7.1 Discontinuation of Study Drug  and Study Stopping Criteria  
7.1.1 Liver  Che
mistry Stopping Criteria  
7.1.2 QTc
 Stopping Criteria  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
Confident
ial Page 41 of 80 7.3 Lost  to Follow -up 
An enrolled participant who has received study drug will be considered lost to follow -up if he or 
she repeatedly fails to return for scheduled visits and is unable to be contacted by the study 
site.  
The following actions must be taken if a participant fails to return to the clinic for a required 
study visit:  
• The site must attempt to contact the participant and reschedule the missed visit as soon as possible and counsel the participant on the importance of maintaining the assigned 
visit schedule and ascertain whether or not the participant wishes to and/or should continue in the study.  
• Before a participant is deemed lost to follow- up, the I nvestigator or designee must  
make every effort to regain contact with the participant (where possible, 2 contact attempts ( eg, telephone calls and/or emails  and, if necessary a  certified letter to the 
participant’s last known mailing address or local equivalent methods). These contact attempts should be documented in the participant’s medical record.  
• Should the participant continue to be unreachable, the participant will be considered to have withdrawn from the study.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 42 of 80 8 STUDY ASSESSMENTS AND PROCEDURES 
• Study procedures and their timing are summarised in the SoE  (Section  1.3); individual 
clinical procedures are described in detail below.  
• Adherence to the study design requirements, including those specified in the SoE , is 
essential and required for study conduct.  
• All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria. The I nvestigator will maintain a screening log to 
record details of all participants screened and to confirm eligibility or record  reasons for 
screening failure, as applicable.  
• The blood collections for midazolam and 1- hydroxymidazolam are the critical 
parameters and need to be done as close to the exact time point as possible. All other 
procedures should be completed as close to the  prescribed/scheduled time as possible, 
but can be performed prior to or after the prescribed/scheduled time. Any 
nonscheduled procedures required for urgent evaluation of safety concerns take 
precedence over all routine scheduled procedures.  
• Repeat or unscheduled samples may be obtained for safety reasons.  
• In the event of a significant study -continuity issue ( eg, caused by a pandemic), alternate 
strategies for participant visits, assessments, medication distribution, and  monitoring 
may be implemented by Indivior or the I nvestigator, as per local health authority/ethics 
requirements.  
Table 3 Blood Volume during the Study  
Sample Type  Number 
of Time 
Points Approximate 
Volume per Time Point * (mL)  Approximate Sample 
Volume Over Course 
of Study (mL)  
Screening laboratory safety tests 
(including ha ematology, serum chemistry, 
serology, and coagulation), FSH (for PMP 
female participants only) and serum 
pregnancy (for female participants  only).  1 16 16 
On-study h aematology , serum chemistry  8 12.5  100 
On-study coagulation ( prothrombin 
time /International normalised ratio [ INR] 
and activated partial thromboplastin 
time ) 4 3.5 14 
Blood for Midazolam and 1-hydroxymidazolam PK  32 4 128 
Total Blood Volume (mL)→  294 ** 
* Represents the largest collection tube that is expected to be used (a smaller tube may be used).  
** If additional safety  or PK analysis are necessary, additional blood may be obtained (up to a maximum of 50 mL).  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 43 of 80 8.1 Administrative  Procedures  
8.1.1 Informed Consent Procedure  
Refer to Section 10.1.3. 
8.1.2 Inclusion and E xclusion Criteria  
Refer  to Section 5.1 and Section 5.2. 
8.1.3 Medical History/Demography 
At screening, medical history and demographic data, including name, sex, age, race, 
ethnicity, psychiatric history, and substance use  will be recorded.   
8.1.4 Concomitant Medications  
Concomitant  medications will be prohibited as listed in Section 6.9. All medications 
taken by  participants during the course of the study will be recorded. 
8.1.5 Check -in Criteria  
Upon passing scre ening and meeting inclusion and not meeting exclusion criteria, the 
participant will be admitted to the study site  on Day -1. Once admitted, participants 
must meet the following criteria prior to Day 1 dosing : 
• A check -in questionnaire will be reviewed for each participant to ensure that 
participants remain eligible for the study since screening. Questions will focus on 
inclusion and exclusion criteria and on study restrictions.  
• Female participants must have a negative urine pregnancy test.  
• Participants mus t have a negative result obtained from the urine drug screen and 
the alcohol  test.  
• Participants must have a negative polymerase chain reaction test result for COVID -19. 
If any of these criteria are not met, the participant will not be enrolled.  
8.2 Efficacy and/or Immunogenicity  Assessments  
Efficacy and/or immunogenicity  are not evaluated in this study . 
8.3 Safety Assessments  
Planned time points for all safety assessments are provided in the SoE  (Section  1.3). Individual 
clinical procedures are described in detail below.  
Additional safety assessments may be  performed at various unscheduled time points, if 
deemed necessary by the I nvestigator or designee.  
8.3.1 Physical Examinations  
• Physical examination will be conducted as outlined in the So E (Section  1.3).  
• Male participants will undergo a testicular exam as outlined in the SoE ( Section  1.3).  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 44 of 80 • Addi tional physical examinations may be performed at other times, if deemed necessary 
by the Investigator or designee.  
• A complete physical examination will include, at a minimum, an examination of all major 
body/organ systems (including skin, head, eyes, ears,  nose, throat, neck, thyroid, lungs, 
heart, abdomen, lymph nodes, and extremities). Height and weight (with participants wearing indoor, daytime clothing with no shoes) will also be measured and recorded as 
outlined in the So E (Section  1.3).  
8.3.2 Vital Signs  
• Single v ital signs will include the collection of oral body temperature , respiratory rate, 
blood pressure, and pulse rate and will be conducted as outlined in the SoE (Section  1.3).  
• Blood pressure and pulse measurements will be assessed with a completely automated device. Manual techniques will be used only if an automated device is not available.  
• Blood pressure and pulse rate will be assessed with the participant resting in a seated 
position for at least 5 minutes, except when participants are supine or semi -reclined 
because of study procedures and/or AEs (eg, nausea, dizziness)  or if deemed necessary 
by the Investigator or designee.  
• When scheduled pre -dose, vital signs will be measured within 2 hours prior to morning 
dosing for the pre -dose morning time points. When scheduled post- dose, vital signs will 
be performed within approximately 15 minutes of the scheduled time po int. 
8.3.3 Electrocardiograms  
• Single 12 -lead ECG will be conducted as outlined in the So E (Section  1.3) using an ECG 
machine that automatically calculates the heart rate and measures PR, QRS, QT, and QTcF intervals.  
• ECGs will be performed with participants resting  in a supine position for at least 
5 minutes. All ECG tracings will be reviewed by the I nvestigator or designee.  
• When scheduled pre -dose, ECGs will be measured within 2 hours prior to morning 
dosing. When scheduled post- dose, ECGs will be performed within approximately 
20 minutes of the  scheduled time point.  
8.3.4 Pulse Oxymetry  
• Pulse oximetry reading will be collected using a pulse oximeter (oxygen levels as saturation [%]) as outlined in the SoE ( Section  1.3).  
• Where the time of reading coincides with a blood sampling time point, the reading will 
be collected within approximately 10 minutes prior to the scheduled time point. 
Readings may be taken at other times, if deemed necessary by the Investigator or 
designee.  
• Any oxygen saturation reading deemed clinically significant by the Investigator will be 
documented as an AE . 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 45 of 80 8.3.5 Clinical Safety Laboratory Tests 
• See Section  10.2 (a ppendix) for the list of clinical laboratory tests to be performed and 
to the SoE (Section  1.3) for the timing and frequency.  
• The I nvestigator must review the laboratory re sults , document this review and record 
any clinically relevant changes occurring during the study as an  AE. The laboratory 
results must be retained with the source documents.  
• All laboratory tests with values considered clinically significantly abnormal during 
participation in the study should be repeated until the values return to normal or baseline or are no longer considered clinically significant by the I nvestigator or medical 
monitor.  
o If such values do not return to normal/baseline within a period of time judged 
reasonable by the Investigator, the etiology  should be identified and Indivior  
notified. 
o All protocol- required laboratory tests , as defined in Section  10.2  (appendix), must be 
conducted in accordance with the laboratory manual and the So E (Section 1.3). 
o If laboratory values from non –protocol -specified laboratory tests performed at the 
institution’s local laboratory require a change in participant management or are 
considered clinically significant by the I nvestigator ( eg, SAE or AE or dose 
modification), then the results must be recorded.  
o Serum chemistry tests will be performed after at least an 12- hour fast; however, in 
case of dropouts or rechecks, participants may not have fasted for 12 hours prior to 
when the serum chemistry sample is taken.  
8.3.6 Pregnancy Testing  
• Pregnancy testing will be conducted at as outlined in the SoE ( Section 1.3). 
• In the case where a participant’s routine pregnancy test as required per protocol is 
positive for pregnancy prior to dosing, the participant should not be dosed. If the 
participant has a positive urine pregnancy test, a confirmatory serum pregnancy test should be performed.  
• Additional pregnancy tests may be  performed, as determined necessary by the 
Investigator or required by local regulation, to establish the absence of pregnancy at any 
time during the study.  
8.3.7 Suicidal Ideation and Behaviour Risk Monitoring  
• The C -SSRS is a questionnaire scale to detect emerg ent suicide symptoms (suicidal 
ideation or actual suicidal behavio ur). Baseline evaluations will assess the lifetime 
experience of the participant  with suicidal ideation and behavio ur and post baseline 
evaluation s will focus on suicidality since the last study visit.  
• C-SSRS questionnaire will be conducted as outlined in the SoE ( Section 1.3); the 
Baseline/Screening C -SSRS vers ion will be completed at screening (lifetime history and 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 46 of 80 past 6 months) and the Since Last Visit C -SSRS version will be comp leted at all other 
time points.  
• On Day 8 and Day 15, C -SSRS will be conducted within 1 hour of the scheduled time 
point.  
• Additional C-S SRS assessment may be performed at other times if deemed necessary by 
the Investigator or designee.  
• The C -SSRS is to be administered at the site by an appropriately qualified/trained 
individual and a copy of the questionnaire to be used will be kept in the study binder. In 
addition, participants who at any time during this study spontaneously report AEs of suicidal ideation or suicidal behavio ur must be assessed by the Investigator or designee 
and referred for further mental health evaluation as clinically indicated.  
8.3.8 Sedation VAS  
• VAS will be conducted as outlined in the SoE ( Section 1.3)  
• When scheduled pre -dose, VAS will be measured within 1 hour prior to morning dosing. 
When scheduled post- dose, VAS will be performed within approximately 5 minutes for 
the 30-minute scheduled tim e point and within 10 minutes for the 1 -hour and 2 -hour 
scheduled time points. 
• The VAS to be used will be provided in a separate document.  
8.4 Adverse Events , Serious Adverse Events , and Other Safety Reporting  
The definitions of AEs and SAEs  are provided below, as are criteria for assessment of AE/SAE 
intensity and causality.  
The I nvestigator and any qualified designees are responsible for detecting, documenting , and 
recording events that meet the definition of an AE or SAE and remain responsible for following up AEs that are serious, considered related to the study drug or study procedures or that caused the participant to discontinue the study drug (see Section  7). 
AE Definition  
• An AE is any untoward medical occurrence in a patient or clini cal study participant, 
temporally associated with the use of study drug, whether or not considered related to the study drug.  
• NOTE: An AE can therefore be any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally 
associated with the use of study drug.  
Events Meeting the AE Definition  
• Any abnormal laboratory test results (h aematology, clinical chemistry , coagulation, or 
urinalysis) or other safety assessments ( eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from screening (signing of the ICF), 
considered clinically significant in the medical and scientific judgement of the Investigator ( ie, not related to progression of underlyi ng disease , or more severe than 
expected for the participant’s condition).  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 47 of 80 • Exacerbation of a chronic or intermittent pre -existing condition including either an 
increase in frequency and/or intensity of the condition.  
• New conditions detected or diagnosed after study drug administration even though it 
may have been present before signing the ICF . 
• Signs, symptoms , or the clinical sequelae of a suspected DDI or that resulted in 
additional intervention ( eg, concomitant medication, surgery).  
• Signs, symptoms, or the clinical sequelae of a suspected overdose of either study drug 
or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self- harming intent. Such 
overd oses should be reported regardless of sequelae.  
Events not meeting the AE definition 
• Any abnormal laboratory findings or other abnormal safety findings that are not considered to be clinically significant by the Investigator. 
• Medical or surgical procedure (eg, endoscopy, appendectomy): the condition that leads to the procedure is the AE.  
• Situations in which an untoward medical occurrence did not occur (social and/or convenience admission to a hospital, hospitalisation for elective surgery, hospitalisation for observation in the absence of an AE).  
Definition of SAE  
An SAE is defined as any untoward medical occurrence that:  
a. Results in death 
b. Is life -threatening  
The term “ life-threatening” in the definition of “serious ” refers to an event in which the 
participan t was at risk of death at the time of the event. It does not refer to an event, which 
hypothetically might have caused death, if it were more severe.  
c. Requires inpatient hospitalisation or prolongation of existing hospitalisation • In general, hospitalisation signifies that the participant r equires inpatient 
HOSPITALIS ATION or prolongation of existing hospitali sation  and/or treatment that 
would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospitalisation are AEs. If a complication prolongs hospitalisation or fulfils any other serious criteria, the event is serious. When in doubt as to whether “hospitalisation” occurred or was necessary, the AE should be considered 
serious.  
• Hospitalisation for elective treatment of a pre -existing condition that did not worsen 
from screening (signing of the ICF) is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s  ability to conduct 
normal life functions.  
• This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhoea, influenza, 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 48 of 80 and accidental trauma ( eg, sprained ankle) wh ich may interfere with or prevent 
everyday life functions but do not constitute a substantial disruption.  
e. Is a congenital anomaly/birth defect 
f. Other situations:  
• Medical or scientific judgement should be exercised in deciding whether SAE reporting 
is approp riate in other situations such as important medical events that may not be 
immediately life -threatening or result in death or hospitalisation but may jeopardise the 
participant or may require medical or surgical intervention to prevent one of the other outcomes listed in the above definition. These events should usually be considered serious.  
o Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency room or at home for allergic bronchospasm, blood dyscrasias or 
convu lsions that do not result in hospitalisation, or development of study drug 
dependency or study drug  abuse. 
• An SAE must be reported for participants with alanine aminotransferase (ALT)  or 
aspartate aminotransferase (AST) ≥3  × upper limit of normal ( ULN ) and bilirubin 
≥2 × ULN (>35% direct).  
Definition of SUSAR  
A suspected unexpected serious adverse reaction  (SUSAR ) is an SAE with at least a 
reasonable possibility of being related to the study drug ( ie, the relationship cannot be ruled 
out), the nature or  severity of which is not consistent with the applicable product 
information ( eg, IB for an unapproved investigational product or package insert/summary of 
product characteristics for an approved product).  
Assessment of Intensity  
The I nvestigator will asse ss intensity for each AE and SAE reported during the study and assign 
it to 1 of the following categories:  
• Mild: A type of AE  that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event does not generally interfere with usual activities of 
daily living . 
• Moderate: A type of AE  that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no significant or permanent risk of harm to the research participant.  
• Severe: A type of AE  that interrupts usual activities of daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
Assessment of Toxicitiy  
Separately, the toxicity of AEs will be graded in accordance with the FDA Guidance for Industry: 
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers  Enrolled in Preventive 
Vaccine Clinical Trials ( Section 10.7). Any event not falling under one of the specific categories 
listed will be graded as a “Systemic Illness”.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 49 of 80 For events that o ccur after first study drug administration, the maximum intensity, toxicity , and 
seriousness should be reflected in the event record.  
Assessment of Causality 
• The I nvestigator is obligated to assess the relationship between study drug and each 
occurrence of each AE/SAE.  The relationship of each AE to study drug will be assessed 
using the following categories:  
o Related : An AE that follows a reasonable temporal sequence  from administration of 
a drug (including the course after withdrawal of the drug), or for which a causal 
relationship is at least a reasonable possibility, ie, the relationship cannot be ruled out, although factors other than the drug, such as underlying diseases, complications, concomitant drugs and concurrent treatments, may also be 
responsible. 
o Not Related : An AE that does not follow a reasonable temporal sequence from 
administration of a drug and/or that can reasonably be explained by other factors, 
such as underlying diseases, complications, concomitant medications and 
concurrent treatments.  
• The Investigator will use clinical judg ement  to determine the relationship.   
• Alternative causes, such as underlying disease(s), concomitant therapy, and other ris k 
factors, as well as the temporal relationship of the event to study drug administration will be considered and investigated.  
• For causality assessment, the I nvestigator will also consult the IB and/or product 
information , for marketed products.  
• The I nvestigator must review and provide an assessment of causality f or each AE/SAE  
and document this in the medical notes.  There may be situations in which an SAE has 
occurred and the I nvestigator has minimal information to include in the initial report to 
Indivior. However, it is very important that the I nvestigator always make an assessment 
of causality for every event before the initial transmission of the SAE data to Indivior . 
• The I nvestigator may change opinion of causality in light of follow -up information and 
send a n SAE follow -up report with the updated causality assessment.  
• The causality assessment is one of the criteria used when determining regulatory reporting requirements.  
Clinical Laboratory Changes 
Changes in laboratory values, vital signs , or oth er safety parameters ( eg, neurological and 
clinical symptom assessments) as noted in the protocol are a subset of AEs and are reportable 
only if the laboratory  test result is associated with accompanying symptoms, and/or requires 
additional diagnostic testing or intervention (medical, surgical), and/or requires additional significant treatment, and/or requires temporal or permanent discontinuation of study drug or a change to dosing other than as permitted by protocol, or if considered to be clinically significant by Investigator or medically qualified designee.  
Screening laboratory assessments, if determined to be clinically significant by the Investigator , 
are not AEs.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 50 of 80 8.4.1 Time Period and Frequency for Collecting AE and SAE Information 
All AEs and SAEs will be collected from ICF signature  until the EOS  Visit on Day 22 ( ±2 days) or at 
early termination . Any ongoing AEs  at the time of the EOS  Visit (ie , Day 22 [±2 days] ) or at early 
termination will be appropriately followed -up until resolution or 14  days after the EOS Visit or 
early termination . Any ongoing SAEs will be followed -up until resolution or lost to follow -up. 
All SAEs will be recorded and reported to Indivior  or designee immediately and under no 
circumstance should this exc eed 24 hours from first becoming aware of the event, as indicated 
in Section  8.4.3. The I nvestigator will submit any updated SAE data to Indivior  within 24  hours 
of it being available.  
Investigators are not obligated to actively seek AEs or SAEs after conclusion of the study 
participation. However, if the I nvestigator learns of any SAE, including a death, at any time after 
a participant has been discharged from the study, and the Investigator considers the event to 
be reasonably related to the study drug or study participation, the I nvestigator must promptly 
notify Indivior . 
8.4.2 Method of Detecting AEs and SAEs  
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open- ended and 
nonleading verbal questioning of the participant is the preferred method to i nquire about AE 
occurrences.  
8.4.3 Reporting and Follow -up of AEs and SAEs  
After the initial AE/SAE report, the I nvestigator is required to proactively follow each 
participant at subsequent visits/contacts. All SAEs will be followed until resolution, stabilis ation, 
the event is otherwise explained or the participant is lost to follow up (as defined in 
Section  7.3). Further information on follow  up procedures is provided in Section  8.4.3.2. 
Once the I nvestigator determines that an event meets the protocol definition of an SAE, the 
SAE will be reported to Indivior (or designated representative) by the I nvestigator (or designee) 
within 24 hours from first being aware of the event using the form provided by Indivior or designated representative. Any follow up information on a previously reported SAE will also be 
reported to Indivior within 24 hours.  
Where additional information is n eeded or expected, the I nvestigator will not wait to receive all 
information before reporting the event to Indivior. The I nvestigator must provide an 
assessment of causality at the time of the initial report as described in Section  8.4.  
8.4.3.1  Reporting of SAEs  
SAE Reporting to Indivior via Paper SAE Reporting Form  
• The primary mechanism for reporting an SAE to Indivior Pharmacovigilance will be by completing the paper SAE Reporting Form provided by Indivior. Follow -up information 
will also be reported using the paper SAE Reporting Form.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 51 of 80 o The SAE Reporting Form should be completed and submitted to Indivior 
Pharmacovigilance:  
• The site will report all SAEs within 24 hours from first being aware of the event. Any 
follow -up information on a previously reported SAE will also be reported to Indivior 
within 24 hours.  
8.4.3.2  Recording and Follow -up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the I nvestigator to review all 
documentation ( eg, hospital progress notes, laboratory reports , and diagnostics reports) 
related to the event.  
• The I nvestigator will then record all relevant AE/SAE information in the e CRF.   
• It is not acceptable for the I nvestigator to send photocopies of the participant’s medical 
records to Indivior  in lieu of completion of the required form . 
• There may be instances when copies of medical records for certain cases are requested 
by Indivior Pharmacovigilance. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copies of the medical records before 
submission to Indivior Pharmacovigilance . 
• The I nvestigator will attempt to establish a diagnosis of the event based on signs, 
symptoms and/or other clinical information. Whenever possible, the diagnosis (not the 
individual signs/symptoms) will be documented as the AE /SAE.  
Follow -up of AEs and SAEs  
• The I nvestigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by Indivior 
Pharmacovigilance to elucidate the nature and/or causalit y of the AE or SAE as fully as 
possible. This may include additional laboratory tests or investigations, histopathological 
examinations , or consultation with other health care professionals.  
• New or updated information will be recorded in the originally sub mitted documents . 
• The I nvestigator will submit any updated SAE data to Indivior  within 24 hours of receipt 
of the information.  
• After the initial AE/SAE report, the Investigator is required to proactively follow each  
participant at subsequent visits/contacts. All SAEs will be followed until resolution, 
stabilisation , the event is otherwise explained, or the participant is lost to follow- up (as 
defined in Section 7.3).  
8.4.4 Regulatory Reporting Requirements for SAEs  
• Prompt notification by the I nvestigator to Indivior  of an SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study drug under clinical investigation are met.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 52 of 80 • Indivior  has a legal responsibility to notify both the local regulatory authority and other 
regulatory agencies about the safety of a study drug under clinical investigation. Indivior  
will comply with country -specific regulatory requirements relating to safety reporting to 
the regulatory authority, IRB/IEC, and I nvestigators . 
• An Investigator who receives an Investigator safety report describing an SAE or other 
specific safety information ( eg, summary or listing of SAEs) from Indivior  will review and 
then file it along with the IB  and/or package insert and will notify the IRB/IEC, if 
appropriate according to local requirements.  
• Investigator safety reports must be prepared for SUSAR according to local regulatory 
requirements and Indivior  policy and forwarded to I nvestigators as necessary.  
8.4.5 Pregnancy  
• Details of all pregnancies in female participants  and in female partners of male 
participants will be collected after the first study drug administration and until 90 days 
following the last dose.   
• If a pregnancy is reported, the Investigator will record pregnancy information on the 
appropriate form and submit it to  Indivior  within 24 hours of learning of the female 
participants and in female partners of male partic ipants (after obtaining the necessary 
signed informed consent from the female partner) pregnancy .  
• While pregnancy itself is not considered to be an AE or SAE, any pregnancy complication 
or elective termination of a pregnancy for medical reasons will be reported as an AE or 
SAE.  
• All pregnancy exposure cases (unless permission has been denied), where the embryo or foetus may have been exposed to study drug (either through maternal exposure or transmission of a medicinal product via semen following paternal e xposure) whether 
associated with an AE or not, will be followed in order to collect information on the 
outcome of the pregnancy ( ie, termination [voluntary or spontaneous] or birth). Make 
2 attempts to obtain information after the expected due date, with 1 month between 
the 2 attempts. If there is no response, the case will be closed.  
• Abnormal pregnancy outcomes ( eg, foetal death, stillbirth, congenital anomalies, 
ectopic pregnancy, abortion [except pregnancy in habitual aborter, prophylaxis of 
aborti on], pre -eclampsia, eclampsia) are considered SAEs  and will be reported as such. 
• The female participants and in female partners of male participants will be followed to 
determine the outcome of the pregnancy. The I nvestigator will collect follow -up 
information on the female participants and in female partners of male participants and 
the neonate and the information will be forwarded to Indivior . 
• Any poststudy pregnancy -related SAE considered reasonably related to the study drug 
by the Investigator will be reported to Indivior  as described in Section  8.4.4. While the 
Investigator is not obligated to actively seek this information in former female 
participants and in female partner s of male participants, he or she may learn of an SAE 
through spontaneous reporting.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 53 of 80 • Any female participant who becomes pregnant while participating in the study will be 
withdrawn from the study . 
8.5 Pharmacokinetics  
8.6 Pharmacodynamics  
Pharmacodynamics are not evaluated in this study.  
8.7 Genetics  
Genetics are not evaluated in this study.  
8.8 Biomarkers 
Biomarkers are not evaluated in this study.  
8.9 Health Economics  OR Medical Resource Utilisation and Health Economics  
Health economics  OR Medical resource utilisation and health economics  parameters are not 
evaluated in this study.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 54 of 80 9 STATISTICAL CONSIDERATIONS 
9.1 Statistical  Hypotheses  
There are no formal statistical hypoth eses for this study .  
The primary objective of the study is to determine changes in primary PK parameters of 
midazolam and 1 -hydroxymidazolam. These changes will be estimated by calculating the 
geometric mean ratio ( GMR ) of each primary PK parameter with and without INDV -2000, where 
“with” is considered the test treatment and “without” is considered the reference. Ninety 
(90)% confidence intervals  for the GMR s will be calculated . 
9.1.1 Multiplicity Adjustment  
There are no inferential statistics for this study; therefore, multiplicity adjustment  is not 
applicable .  
9.2 Analyses Sets  
For purposes of analysis, the following populations are defined:  
Table 4 Populations for Analysis  
Population  Description  
Screened  All participants who sign the ICF.  
PK Analysis Set  All participants  who receive at least one dose of study drug and have 
an adequate number of PK samples collected to derive any PK parameter, and have no protocol deviation s that would 
significantly alter plasma concentratio ns of study drug s. All 
available data will be included in the concentration and PK parameter tables to the extent possible. Data for each participant  will be included in the summary statistics and 
statist ical comparisons of PK parameters .  
Safety Analysis Set  All participants who receive at least 1 dose of study drug.  
 
9.3 Statistical  Analyses  
9.3.1 General Considerations  
The statistical analysis plan  (SAP)  will be finalis ed prior to database lock and it will include a 
more technical and detailed description of the statistical analyses described in this section. The 
SAP will be prepared by Indivior . This section is a summary of the planned statistical analyses of 
the most important endpoints including primary and secondary endpoints.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 55 of 80 9.3.2 Primary Endpoints Analysis  
For both midazolam and 1 -hydroxymidazolam, C max, AUC 0-∞, and AUC last in the presence (Day 15) 
of INDV -2000 will be compared to Cmax, AUC 0-∞, and AUC last, respectively, in the absence (Day 1) 
of INDV -2000 using GMRs and 90% CIs calculated using random effects models. The primary 
endpoints will be analy sed using the PK  Analys is Set.  Details on the statistical analyses will be 
included in the SAP.  
9.3.3 Secondary  Endpoints  A nalysis  
TEAEs will be defined as AEs that start on or after the first dose of study drug and will be 
summaris ed by Medical Dictionary for Regulatory Activities system organ class and preferred 
term. TEAEs will be summaris ed for the Safety Analysis Set.   
9.3.4 Tertiary/Exploratory Endpoints  Analysis  
9.4 Interim  Ana
lysis  
No interim analysis is planned.  
9.5 Sample Size Determination  
Approximately 20 participants will be assigned to receive study drug. This sample size is based on earlier clinical experience and is expected to provide at least 16 evaluable participants, defined as participants with plasma concentration- time profiles su fficient for calculation of PK 
parameters during the study.  
 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 56 of 80 10 SUPPORTING DOCUMENTATION AND OPERATIONAL CONSIDERATIONS 
10.1 Appendix  1: Regulatory, Ethical , and Study Oversight Considerations  
10.1.1  Regulatory and Ethical Considerations  
• This study will be conducted in accordance with the protocol and with the following:  
o Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences international ethical guidelines  
o Applicable ICH GCP  guidelines 
o Applicable laws and regulations  
• The protocol, protocol amendments, ICF, IB , and other relevant documents ( eg, 
advertisements) must be submitted to an IRB/IEC by the Investigator and reviewed and 
approved by the IRB/IEC before use in  the study. If required by local regulations, the 
protocol should be re -approved by the IRB/IEC annually. The IRB/IEC must be 
constituted and operate in accordance with the principles and requirements of ICH/GCP.  
• Any amendments to the protocol will require IRB/IEC approval before implementation 
of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants.  
• Protocols and any substantial amendments to the protocol may  require heal th authority 
approval prior to initiation except for changes necessary to eliminate an immediate hazard to study participants.  
• The I nvestigator will be responsible for the following , as applicable : 
o Providing written summaries of the status of the study to the IRB/IEC annually or more frequently in accordance with the requirements, policies, and procedures established by the IRB/IEC  
o Notifying the IRB/IEC of SAEs or other significant safety findings as required by IRB/IEC procedures  
o Providing oversight of the  conduct of the study at the site and adherence to 
requirements of 21 Code of Federal Regulations ( CFR), ICH guidelines, the 
IRB/IEC, European regulation 536/2014 for clinical studies , European Medical 
Device Regulation 2017/745 for clinical device researc h, and all other applicable 
local regulations  
10.1.2  Financial Disclosure  
Investigators and sub investigators will provide Indivior  with sufficient, accurate financial 
information (when applicable) as requested to allow Indivior  to submit complete and accurate 
financial certification or disclosure statements to the appropriate regulatory authorities. Investigators are responsible for p roviding information on financial interests during the course 
of the study and for 1 year after completion of the study.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 57 of 80 10.1.3  Informed Consent Process  
• The I nvestigator or the Investigator’s representative will explain the nature of the study 
to the participant and answer all questions regarding the study.  
• Potential participants must be informed that their participation is voluntary. They  will be 
required to sign a statement of informed consent that meets the requirements of 
21 CFR 50, local regulations, ICH guidelines, and privacy and data protection 
requirements , where applicable, and the IRB/IEC or study centre.  
• Written informed consent must be obtained prior to any study -related .  
• The authorised person obtaining the informed consent must also sign the ICF.  
• Participants must be re consented to the most current version of the ICF(s) during their 
participation in the study , if required by the IRB/IEC . 
• A copy of the ICF(s) must be provided to the participant.  
10.1.4  Data Protection 
• Participants will be assigned a unique identifier by the study site. Any participant records or datasets that are transferred to Indivior  will contain the identifier only; 
participant names or any information wh ich would make the participant identifiable will 
not be transferred.  
• Participant s must be informed that their personal study -related data will be used by 
Indivior  in accordance with local data protection law. The level of disclosure must also 
be explained to the participant who will be required to give consent for their data to be 
used as described in the informed consent.  
• Participant s must be informed that their study records may be examined by Clinical 
Quality Assurance auditors or other authorised perso nnel appointed by Indivior , and by 
inspectors from regulatory authorities.  
• The contract between Indivior and study sites specifies responsibilities of the parties 
related data protection, including handling of data security breaches and respective communic ation and cooperation of the parties.  
• Information technology systems used to collect, process, and store study -related data 
are secured by technical and organi sational security measures designed to protect such 
data against accidental or unlawful loss, alt eration, or unauthori sed disclosure or access.  
10.1.5  Dissemination of Clinical Study Data  
This study will be registered on ClinicalTrials.gov, European Clinical Trials Database , or the 
country’s clinical study registry , as appropriate, and in accordance with national, regional, and 
local regulations . Release of applicable clinical study results will proceed in compliance with 
local regulations in accordance with the principles of Good Publication Practice.  
A clinical study report  will be prepared following completion of the study. An Investigator 
signatory may be identified for the approval of the report if required by applicable regulatory requirements.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 58 of 80 10.1.6  Data Quality Assurance  
• All participant data relating to the study will be recorded on printed or CRF s unless 
transmitted to Indivior  or designee electronically ( eg, laboratory data). The Investigator 
is responsible for verifying that data entries are accurate and correct by physically or 
electronically signing the CRF.  
• Guidance on c ompletion of CRFs will be described in the CRF completion guidelines . 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections , and  provide direct access to source data documents.  
• Investigator Site Audits include, but are not limited to, review of drug supply, presence 
of required documents, the informed consent process, comparison of CRFs with source documents, and any other study -specific information/documentation that the auditor 
deems appropriate for review during the audit. The Investigator agrees to participate 
with audits conducted at a reasonable time in a reasonable manner. Full consultation with the Investigator will be made prior to and during such an audit, which will be 
conducted according to Indivior’s or a Contract Research Organization’s Quality 
Assurance  SOPs.  
• In addition, this study is subject to inspections by regulatory authorities. If such a regulatory inspection occurs, the I nvestigator agrees to allow the regulatory inspector 
direct access to all relevant study documents. The Investigator must contact Indivior 
immediately if this occurs and must fully cooperate with the inspection conducted at a reasonable time in  a reasonable manner.  
• Monitoring details describing strategy including definition of study critical data items and processes ( eg, risk -based initiatives in operations and quality such as risk 
management and mitigation strategies and analytical risk -based monitoring ), methods, 
responsibilities and requirements, including handling of noncompliance issues and 
monitoring techniques (central, remote , or on -site monitoring) are provided in the 
monitoring plan . 
• Indivior  or designee is responsible for t he data management of this study including 
quality checking of the data.  
• Indivior  assumes accountability for actions delegated to other individuals ( eg, contract 
research organisations ). 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by the I nvestigator as dictated by ICH/GCP guidelines, as well as in 
accordance with the site’s Standard Operating Procedure  requirements and local 
regulations or institutional policies. No records may be destroyed without the written 
approval of Indivior . No records may be transferred to another location or party without 
written notification to Indivior . 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 59 of 80 10.1.7  Source Documents  
• Source documents provide evidence for the existence of the participant and 
substantiate the integrity of the data collected. Source documents are filed at the Investigator’s site.  
• The I nvestigator is responsible for the quality of the data recorded in the CRFs. The data 
recorded should be a complete and accurate account of the participant’s record collected  during the study.  
• Data reported on the CRF or entered in the eCRF that are transcribed from source documents must be consistent with the source documents or the discrepancies must be explained. The I nvestigator may need to request previous medical records  or transfer 
records, depending on the study. Also, current medical records must be available.   
• Source documents may be electronic, hard copy, or a combination of both and are defined as the results of original observations and activities of a clinical inv estigation. 
When using a direct entry CRF, the CRF will be considered the source document for applicable CRF elements collected directly onto a CRF. Source documents will include, but are not limited to, progress notes, electronic data, screening logs , and recorded data 
from automated instruments. All source documents pertaining to this study will be maintained by the Investigator and made available for direct inspection by the 
authorised study personnel outlined in the ICF.   
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF.  
• Indivior  or designee will perform monitoring to confirm that data entered into the CRF 
by authori sed site personnel are accurate, complete, and verifiable from sourc e 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any 
other study agreements, ICH GCP, and all applicable regulatory requirements.  
10.1.8  Study  and Site  Start and Closure  
First Act of Recruitment  
The study start date is the date on which the clinical study will be open for recruitment of participants. 
The first act of recruitment is the time study is published to the call cent re and 
Helpresearch.com website and will be the study start date.  
Study/Site Termination Indivior  or designee reserves the right to close the study site or terminate the study at any time 
for any reason at the sole discretion of Indivior . Study sites will be closed upon study 
completion. A study site is considered closed when all required documents and study supplies 
have been collected and a study -site closure visit has been performed.  
The Investigator may initiate study -site closure at any time, provided there i s reasonable cause 
and sufficient notice is given in advance of the intended termination.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 60 of 80 Reasons for the early closure of a study site by Indivior  or Investigator may include but are not 
limited to  the following : 
For study termination:  
• Discontinuation of further study drug  development 
For site termination:  
• Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC 
or local health authorities, Indivior  procedures , or GCP guidelines  
• Inadequate or no recruitment  (evaluated after a reasonable amount of time)  of 
participants by the Investigator 
• Total number of participants included earlier than expected  
If the study is prematurely terminated or suspended, Indivior  shall promptly inform the 
Investigators , the IRBs /IECs , the regulatory authorities , and any contract research 
organis ation(s) used in the study of the  reason for termination or suspension, as specified by 
the applicable regulatory requirements. The Investigator shall promptly inform the participant 
and should assure appropriate participant therapy and/or follow-up. 
10.1.9  Publication Policy  
The study data will  be owned by Indivior. Publication of any and all data will be at the discretion 
of Indivior. The Investigator will not disseminate, present, or  publish any of the study data 
without the prior written approval from Indivior to do so.  
• Indivior  will comply with the requirements for publication of study results. In 
accordance with standard editorial and ethical practice, Indivior  will generally suppo rt 
publication of multicentre studies only in their entirety and not as individual site data. In 
this case, a coordinating Investigator will be designated by mutual agreement.  
• Authorship will be determined by mutual agreement and in line with International  
Committee of Medical Journal Editors authorship requirements.   
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 61 of 80 10.2 Appendix  2: Clinical Laboratory Tests 
• The tests detailed in Table 5 will be performed by the local laboratory . 
• Protocol -specific requirements for inclusion or exclusion of participants are detailed in 
Section 5. 
• Additional tests may be performed at any time during the study as determined 
necessary by the Investigator or required by local regulations.   
• Pregnancy testing: Female participants should only be enrolled after a negative serum pregnancy test result at s creening and a negative urine pregnancy test result at 
check -in. Additional pregnancy testing will be performed as specified in the SoE 
(Section  1.3) and as deemed necessary by the I nvestigator or required by local 
regulation, to establish the absence of pregnancy at any time during the study.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 62 of 80 Table 5 Protocol -required Safety Laboratory Tests  
Haematology   Serum Chemistry *  
• Haemoglobin  
• Haematocrit   
• Total and differential leukocyte count  
• Red blood cell count 
• Platelet count  
 
Coagulation 
• Prothrombin time/ INR 
• Activated partial thromboplastin 
  • Blood Urea Nitrogen  
• Bilirubin (total and direct)  
• Alkaline phosphatase (ALP) 
• AST 
• ALT 
• Gamma- glutamyl  Transferase  
• Albumin 
• Sodium 
• Potassium  
• Chloride  
• Glucose (fasting)  
• Creatinine **  
• Total protein  
• Total cholesterol  
• Triglycerides  
• Creatine  phosphokinase 
 
Urinalysis   Additional Tests  
• pH 
• Specific gravity  
• Protein ***  
• Glucose  
• Ketones  
• Bilirubin  
• Blood ***  
• Nitrite***  
• Urobilinogen  
• Leukocyte esterase ***   • HIV-1; HIV -2 (screening only)  
• HBsAg  (screening only) 
• HCV  antibodies (screening only)  
• Urine drug screen  
 Opiates § 
 Opioids  
 Amphetamines  
 Barbiturates  
 Benzodiazepines  
 Cocaine  
 Cannabinoids  
 Fentanyl  
 Oxycodone  
• Urine alcohol screen  
• Serum pregnancy test (for females only ; screening 
only ) 
• Urine pregnancy test (for females only)  
• FSH (for PMP females only ; screening only ) 
• COVID- 19 PCR (check -in only)  
 
* Serum chemistry tests will be performed after at least an 12- hour fast; however, in case of dropouts or rechecks, 
participants  may not have fasted for 12 hours prior to when the serum chemistry sample is taken . 
** At the S creening Visit, creatinine clearance will be calculated using the Cockcroft -Gault formula.  
*** If urinalysis is abnormal for protein, blood, nitrite and/or leukocyte esterase, a microscopic examination (for red blood 
cells, white blood cells, bacteria, casts, and epithelial cells) will be performed .  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 63 of 80 10.3 Appendix  3: Contraceptive Guidance and Collection of Pregnancy Information 
10.3.1  Definitions  
Woman of  Nonchildbearing  Potential (WONCBP)  
Women in the following categories are considered WONCBP:  
• Do not have a uterus, or  
• Are surgically sterile ( eg, has undergone complete hysterectomy, bilateral 
oophorectomy, hysteroscopic  sterilization , or tubal ligation), or  
• Have permanent cessation of ovarian function due to ovarian failure or surgical removal 
of the ovaries, or  
• Are post -men opausal as defined by 12 months or more of spontaneous amenorrhea as 
confirmed by a FSH  >30 mIH/mL.  
10.3.2  Contraception Guidance  
Female Participants  
No contraception methods are required as females of childbearing potential will not be eligible 
to enroll in the study. Only females of non- childbearing potential will be enrolled . 
Male Participants  
Male participants with female partners of childbearing potential must comply with the 
following contraception requirements from the time of first dose of study medication until at 
least 90 days  after the last dose of study medication.  
• All non -sterile male participants must use highly effective contraception from first study 
drug adm inistration through 90 days after their last study drug administration if sexually 
active with a non- pregnant partner of child bearing potential. Highly effective 
contraception is defined as:  
o True sexual  abstinence  
o Condom plus partner’s use of:  
 Oral, int ravaginal,  injectables , implants, or transdermal combined 
(estrogen - and progestogen- containing) hormonal contraception 
associated with inhibition of ovulation  
 Intrauterine device  
 Intrauterine hormone -releasing system  
 Bilateral tubal occlusion  
• No restri ctions are required for a vasectomis ed male provided his vasectomy has been 
performed 4 months or more prior to the first dosing. A male who has been 
vasectomis ed less than 4 months prior to the first dosing must follow the same 
restrictions as a non -vasectomi sed male.  
Male participant must agree not to donate sperm from the first dosing until at least 90  days 
after the last dosing.   
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 64 of 80 10.4 Appendix 4: Liver Safety: Suggested Actions and Follow -up Assessments  
The following should occur if a participant meets any of the liver chemistry stopping criteria as 
outlined below: 
Phase I liver chemistry stopping criteria are designed to assure participant safety and to 
evaluate liver event etiology.  
Phase I Liver Chemistry Stopping Criteria and Follow -Up Assessments  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
Confident
ial Page 65 of 80 References  
E
ASL Clinical Practice Guidelines: Drug -induced liver injury. J of Hepatol. 2019; 70 (6):1222- 61. 
James LP, Letzig L, Simpson PM, Capparelli E, Roberts DW, Hinson JA, Davern  TJ, Lee WM. 
Pharmacokinetics of Acetaminophen- Adduct in Adults with Acetaminophen Overdose and 
Acute Liver Failure. Drug Metab Dispos 2009; 37:1779 -84.  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 66 of 80 10.5 Appendix 5: Protocol Amendment History  
Protocol modifications, except those intended to reduce immediate risk to study participants, 
may be made only by Indivior. A protocol change intended to eliminate an apparent immediate hazard to participants may be implemented immediately, pro vided the IRB/IEC is notified 
within 5 days.  
The Protocol Amendment Summary of Changes Table for the current amendment is located directl y before the Table of Contents .  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 67 of 80 10.6 Appendix  6: Pharmacokinetic Sampling Schedule 

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
Confident
ial Page 68 of 80 Table 7
 List of Pharmacokinetic Parameters (non -exhaustive)  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
Confident
ial Page 69 of 80  

INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 70 of 80 10.7 Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in 
Preventive Vaccine Clinical Trials  
Guidance for 
Industry 
Toxicity Grading Scale for 
Healthy Adult and Adolescent 
Volunteers Enrolled in 
Preventive Vaccine Clinical 
Trials 
 
 
Additional copies of this guidance are available from the Office of Communication, Training and Manufacturers Assistance (HFM -40), 1401 Rockville Pike, Suite 200 N , 
Rockville, MD 20852- 1448, or by calling 1 -800- 835- 4709 or 301- 827-1800, or from the 
Internet at http://www.fda.gov/cber/guidelines.htm. 
 
For questions on the content of this guidance, contact the Division of Vaccines and Related Products Applications, Office of Vaccines Research and Review at 301 -827- 3070.  
U.S. Department of Health  and Human Services  
Food and Drug 
Administration
 Center for 
Biologics Evaluation and Research  
September  2007  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 71 of 80 Guidance for Industry  
Toxicity Grading Scale for Healthy Adult and 
Adolescent Volunteers Enrolled in Preventive 
Vaccine Clinical Trials  
 
I. Introduction 
Preventive vaccines are usually d eveloped to prevent disease in a healthy population. The 
Office of Vaccines Research and Review, Center for Biologics Evaluation and Research, regulates 
preventive vaccines under authority of section 351 of the Public Health Service Act (42 U.S.C.262), as well as specific sections of the Federal Food, Drug, and Cosmetic Act, and 
reviews investigational new drug applications (INDs) and biologics license applications (BLAs). (See, for example, Title 21 CFR Parts 312, 600, and 601). Most of the clinical trials of preventive vaccines conducted to support INDs and BLAs enroll healthy volunteers in all phases of vaccine 
testing. The enrolment of healthy volunteers warrants a very low tolerance for risk in those 
clinical trials.  
This guidance provides you, sponsors, monitors, and investigator s of vaccine trials, with 
recommendations on assessing the severity of clinical and laboratory abnormalities in healthy adult and adolescent volunteers enrolled in clinical trials. The grading system described in the table can also be useful in defining a particular study’s stopping rules ( eg, a certain number of 
adverse events, as defined in the table, may call for stopping the study). Less extreme observations ( eg, mild) may not require discontinuing the study vaccine but can still contribute 
to evaluating safety by identifying parameters to focus upon in subsequent product development. Uniform criteria for categoris ing toxicities in healthy volunteers can improve 
comparisons of safety data among groups within the  same study and also between different 
studies. We, FDA, recommend using toxicity grading scale tables, provided below, as a guideline for selecting the assessment criteria to be used in a clinical trial of a preventive vaccine. We recommend incorporation of such appropriate, uniform, criteria into the investigational plan, case report forms, and study reports and correspondence with FDA, sponsors, monitors, 
investigator s, and IRBs.  
This guidance finalizes the draft guidance of the same title dated April 20 05 (70 FR 22664, May 
2, 2005).  
This guidance represents the Food and Drug Administration’s (FDA’s) cur rent thinking on this 
topic. It does not create or confer any rights for or on any person and does not operate to bind 
FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the appropriate FDA staff. If you cannot identify the appropriate FDA staff, call the appropriate number listed on the title page of this guidance.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 72 of 80 FDA’s guidance documents, including this guidance, do not establish legally enforceable 
responsibilities. Instead,  guidances  describe FDA’s current thinking on a topic and should be 
viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word should in FDA’s  guidances  means that something is suggested or 
recommended, but not required.  
II. Background 
Standardized toxicity assessment scales have been widely used to evaluate products treating specific diseases. For example, the National Cancer Institute’s Common Toxicity Criteria Scale and the Division of AIDS’ Toxicity Grading Scale standardize the evaluation of adverse events among patients with cancer and HIV/AIDS, respectively (Refs. 1, 2). The defined toxicity parameters in those scales are designed for patients who may already experience mild, 
moderate, or severe adverse clini cal or laboratory events due to the disease process, and may 
not be appropriate for healthy volunteers.  
In the development of the toxicity grading scales for healthy volunteers, we chose parameter 
limit values based on published information, when such values were available (Refs. 1 -6). For 
example, the Brighton Collaboration has developed case definitions and guidelines to evaluate some adverse events associated with administering vaccines (Ref. 3). In some cases, parameter limit values were based on clinic al experience and experience reviewing vaccine clinical trials 
that enroll normal healthy subjects.  
Toxicity grading scales for laboratory abnormalities should consider the local laboratory reference values when the parameter limit values are defined. The  characteri sation  of 
laboratory parameters among some populations of healthy adults and adolescents may require the exercise of clinical judg ment, for example, consideration of the potential for ethnic 
differences in white blood cell (WBC) counts or gender differences in creatine  phosphokinase 
(CPK) values.  
III. Toxicity grading scale  tables  
Adverse events in a clinical trial of an investigational vaccine must be recorded and monitored and, when appropriate, reported to FDA and others involved in an investigation (sponsors, IRBs, and investigator s). (See, for example, 21 CFR 312.32, 312.33, 312.50, 312.55, 312.56, 312.60, 
312.62, 312.64, 312.66). Although the use of a toxicity grading scale for adverse events would 
not replace these regulatory requirements, using a scale to  categorise  adverse events observed 
during a clinical trial may assist you in monitoring safety and making required reports.  
Nonetheless, we believe that categori sation  or grading of data as outlined in this document is 
supplementary to and should not replace full and complete data analysis.  
These guidelines for toxicity grading scales are primarily intended for healthy adult and 
adolescent volunteers. The parameters in the tables below are not necessarily applicable to every clinical trial of healthy volunteers. The parameters monitored should be appropriate for 
the specific study vaccine. For some preventive vaccines under development, it may be appropriate to include additional parameters to be monitored during a clinical trial or to alte r 
the choice of values in the toxicity table. For example, additional parameters might be added 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 73 of 80 based on one or more of the following: safety signals observed in pre clinical toxicology studies, 
the biological plausibility of the occurrence of certain adver se events, or previous experience 
with a similar licen ced product.  
As discussed above, the tables do not represent a recommendation to monitor all the listed 
parameters in all clinical trials of healthy volunteers, nor do the tables represent all possible 
parameters to be monitored. In addition, these tables do not represent study inclusion or exclusion criteria. We recommend that the parameters monitored be appropriate for the study vaccine administered to healthy volunteers participating in the clinical t rial. 
A. Tables for Clinical Abnormalities  
Local Reaction to 
Injectable Product  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially Life -
Threatening  
(Grade 4)  
Pain  Does not 
interfere with 
activity Repeated use of 
non- narcotic pain 
reliever  
> 24 hours or 
interferes 
with activity  Any use of 
narcotic pain 
reliever or  
prevents daily activity  Emergency room 
(ER) visit or hospitali zation 
Tenderness  Mild discomfort 
to touch  Discomfort 
with 
movement  Significant 
discomfort at 
rest ER visit or 
hospitalization 
Erythema/Redness *  2.5 – 5 cm 5.1 – 10 cm > 10  cm Necrosis or  
exfoliative  
dermatitis  
Induration/Swelling **  2.5 – 5 cm and 
does not 
interfere  
with activity  5.1 – 10 cm 
or interferes with  
activity  > 10  cm or 
prevents daily  
activity  Necrosis  
* In addition to grading the measured local reaction at the greatest single diameter, the measurement should 
be recorded as a continuous variable. 
** Induration/Swelling should be evaluated and graded using the functional scale as well as the actual measurement. 
 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 74 of 80 Vital Signs *  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially 
Life-
Threatening  
(Grade 4)  
Fever (°C)  ** 
(°F) ** 38.0 – 38.4  
100.4 – 101.1  38.5 – 38.9  
101.2 – 102.0  39.0 – 40 
102.1 – 104 > 40  
> 104  
Tachycardia – beats 
per minute  101 – 115 116 – 130 > 130  ER visit or 
hospitalization for 
arrhythmia  
Bradycardia - beats 
per minute***  50 – 54 45 – 49 < 45  ER visit  or 
hospitalization for 
arrhythmia  
Hypertension (systolic) 
- mm Hg  141 – 150 151 – 155 > 155 ER visit or 
hospitalization for malignant  
hypertension  
Hypertension (diastolic) 
- mm Hg  91 – 95 96 – 100 > 100  ER visit or 
hospitalization for malignant  
hypertension  
Hypotension (systolic) 
– mm Hg  85 – 89 80 – 84 < 80  ER visit or  
hospitalization 
for hypotensive 
shock  
Respiratory Rate – 
breaths  
per minute  17 – 20 21 – 25 > 25  Intubation  
* Subject should be at rest for all vital sign  measurements.  
** Oral temperature; no recent hot or cold beverages or smoking.  
*** When resting heart rate is between 60 – 100 beats per minute. Use clinical judgement when  characteris ing bradycardia 
among some healthy subject populations, for example, conditioned athletes.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 75 of 80  
Systemic (General)  Mild (Grade 1)  Moderate  (Grade 2)  Severe ( Grade 3)  Potentially Life  
Threatening 
(Grade 4)  
Nausea/vomiting  No interference  
with activity or 1 – 
2 episodes/24 
hours  Some 
interference with activity or >2 
episodes/24 
hours  Prevents daily 
activity, 
requires  
outpatient 
IV hydration  ER visit or 
hospitalization for 
hypotensive 
shock  
Diarrhea  2 – 3 loose stools  or 
<400 gms/24 hours  4 – 5 stools or  
400 – 800 gms/  
24 hours  6 or more 
watery stools or  
>800gms/24 
hours or requires 
outpatient IV  
hydration  ER visit or 
hospitalization 
Headache  No interference 
with activity  Repeated use of 
non- narcotic pain  
reliever >24 hours or  
some 
interference 
with activity  Significant; any 
use of narcotic 
pain reliever or  
prevents 
daily activity  ER visit or 
hospitalization 
Fatigue  No interference 
with activity Some 
interference with 
activity  Significant;  
prevents 
daily activity  ER visit or 
hospitalization 
Myalgia  No interference 
with activity  Some 
interference with 
activity Significant; 
prevents daily  
activity  ER visit or 
hospitalization 
 
Systemic Illness  Mild (Grade 1)  Moderate(Grade 2)  Severe (Grade 3)  Potentially Life -
Threatening  
(Grade 4)  
Illness or clinical 
adverse event (as 
defined according to 
applicable regulations)  No interference 
with activity  Some 
interference with 
activity not 
requiring medical  
intervention  Prevents daily 
activity and 
requires 
medical 
intervention  ER visit or 
hospitalization 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 76 of 80 B. Tables for Laboratory  Abnormalities  
The laboratory values provided in the tables below serve as guidelines and are dependent upon 
institutional normal parameters. Institutional normal reference ranges should be provided to demonstrate that they are appropriate.  
Serum1 Mild (Grade 1)  Moderate 
(Grade 2)  Severe 
(Grade 3)  Potentially Life  
Threatening 
(Grade 4)2 
Sodium – Hyponatremia mEq/L  132 – 134 130 – 131 125 – 129 <125  
Sodium – Hypernatremia mEq/L  144 – 145 146 – 147 148 – 150 >150  
Potassium – Hyperkalemia mEq/L  5.1 – 5.2 5.3 – 5.4 5.5 – 5.6 >5.6  
Potassium – Hypokalemia mEq/L  3.5 – 3.6 3.3 – 3.4 3.1 – 3.2 <3.1  
Glucose – Hypoglycemia mg /dL 65 – 69 55 – 64 45 – 54 <45 
Glucose – 
Hyperglycemia 
Fasting – mg/dL  
Random – mg/dL   
100 – 110 
110 – 125  
111 – 125 
126 – 200  
>125 
>200 Insulin 
requirements 
or 
hyperosmolar 
coma  
Blood Urea Nitrogen  
(BUN) mg/dL  23 – 26 27 – 31 > 31  Requires  
dialysis  
Creatinine – mg/dL  1.5 – 1.7 1.8 – 2.0 2.1 – 2.5 >2.5 or requires 
dialysis  
Calcium – hypocalcemia mg/dL  8.0 – 8.4 7.5 – 7.9 7.0 – 7.4 <7.0  
Calcium – hypercalcemia mg/dL  10.5 – 11.0  11.1 – 11.5  11.6 – 12.0  >12.0  
Magnesium – 
hypomagnesemia  mg/dL  1.3 – 1.5 1.1 – 1.2 0.9 – 1.0 <0.9  
Phosphorous – 
hypophosphatemia  mg/dL  2.3 – 2.5 2.0 – 2.2 1.6 – 1.9 <1.6  
CPK– mg/dL  1.25 – 1.5 x  
ULN3 1.6 – 3.0 x ULN  3.1 –10 x ULN  >10 x ULN  
Albumin – Hypoalbuminemia g/dL  2.8 – 3.1 2.5 – 2.7 <2.5  -- 
Total Protein – 
Hypoproteinemia  g/dL  5.5 – 6.0 5.0 – 5.4 <5.0  -- 
Alkaline phosphate – 
increase by factor  1.1 – 2.0 x ULN  2.1 – 3.0 x ULN  3.1 – 10 x ULN  >10 x ULN  
Liver Function Tests –ALT, AST  
increase by factor  1.1 – 2.5 x ULN  2.6 – 5.0 x ULN  5.1 – 10 x ULN  >10 x ULN  
Bilirubin – when accompanied  
by any increase in Liver Function 
Test increase by factor  1.1 – 1.25 x ULN  1.26 – 1.5 x ULN  1.51 – 1.75 x ULN  >1.75 x ULN  
Bilirubin – when Liver Function Test  
is normal; increase by factor  1.1 – 1.5 x ULN  1.6 – 2.0 x ULN  2.0 – 3.0 x ULN  >3.0 x ULN  
Cholesterol  201 – 210 211 – 225 > 226  --- 
Pancreatic enzymes – amylase, 
lipase  1.1 – 1.5 x ULN  1.6 – 2.0 x ULN  2.1 – 5.0 x ULN  >5.0 x ULN  
1 The laboratory values provided in the tables serve as guidelines and are dependent upon institutional normal parameters. 
Institutional normal reference ranges should be provided to demonstrate that they are appropriate. 
2 The clinical signs or symptoms associated with laboratory abnormalities might result in  characteris ation  of the laboratory 
abnormalities as Potentially Life- Threatening (Grade 4). For example. a low sodium value that falls within a grade 3 
parameter (125 -129 mE/L) should be recorded as a grade 4 hyponatremia event if the participant  had a new seizure 
associated with the low sodium value.  
3ULN is the upper limit of the normal range.  
I N D V- 2 0 0 0  I n di vi or  
Cli nic al St u dy Pr ot oc ol: I N D V- 2 0 0 0 -1 0 4 Fi n al, A m e n d m e nt 1  1 0 A pr 2 0 2 3  
 
C o nfi d e nti al  P a g e 7 7  of 8 0  H e m at ol o g y 1 Mil d ( Gr a d e 1)  M o d er at e 
( Gr a d e 2)  S e v er e ( Gr a d e 3)  P ot e nti all y 
Lif e- 
T hr e at e ni n g  
( Gr a d e 4)  
H e m o gl o bi n ( F e m al e) - g m/ dL  1 1. 0 – 1 2. 0  9. 5 – 1 0. 9  8. 0 – 9. 4  < . 0  
H e m o gl o bi n ( F e m al e)  
c h a n g e fr o m b as eli n e 
v al u e - g m/ dL  A ny d ecr e as e – 
1. 5  1. 6 – 2. 0  2. 1 – 5. 0  > . 0  
H e m o gl o bi n ( M al e) - g m/ dL  1 2. 5 – 1 3. 5  1 0. 5 – 1 2. 4  8. 5 – 1 0. 4  < 8. 5  
H e m o gl o bi n ( M al e)  
c h a n g e fr o m b as eli n e 
v al u e  – g m/ dL  A ny d ecr e as e – 
1. 5  1. 6 – 2. 0  2. 1 – 5. 0  > 5. 0  
W B C I ncr e as e - c ell/ m m 3 1 0, 8 0 0 – 1 5, 0 0 0  1 5, 0 0 1 – 2 0, 0 0 0  2 0, 0 0 1 – 2 5, 0 0 0  > 2 5, 0 0 0  
W B C D ecr e as e - c ell/ m m 3 2, 5 0 0 – 3, 5 0 0  1, 5 0 0 – 2, 4 9 9  1, 0 0 0 – 1, 4 9 9  < 1, 0 0 0  
L y m p h oc yt es D ecr e as e - c ell/ m m 3 7 5 0 – 1, 0 0 0  5 0 0 – 7 4 9  2 5 0 – 4 9 9  < 2 5 0  
N e utr o p hils D ecr e as e - c ell/ m m 3 1, 5 0 0 – 2, 0 0 0  1, 0 0 0 – 1, 4 9 9  5 0 0 – 9 9 9  < 5 0 0  
E osi n o p hils - c ell/ m m 3 6 5 0 – 1 5 0 0  1 5 0 1 - 5 0 0 0  > 5 0 0 0  H y p er e osi n o p hilic  
Pl at el ets D ecr e as e d - c ell/ m m 3 1 2 5, 0 0 0 – 
1 4 0, 0 0 0  1 0 0, 0 0 0 – 1 2 4, 0 0 0  2 5, 0 0 0 – 9 9, 0 0 0  < 2 5, 0 0 0  
P T – i ncr e as e by f act or  
( pr ot hr o m bi n ti m e)  1. 0 – 1. 1 0 x  
UL N 2 1. 1 1 – 1. 2 0 x UL N  1. 2 1 – 1. 2 5 x UL N  > 1. 2 5 UL N  
P T T – i ncr e as e b y f act or 
( p arti al t hr o m b o pl asti n 
ti m e)  1. 0 – 1. 2 x UL N  1. 2 1 – 1. 4 x UL N  1. 4 1 – 1. 5 x UL N  > 1. 5 x UL N  
Fi bri n o g e n i ncr e as e - m g/ dL  4 0 0 – 5 0 0  5 0 1 – 6 0 0  > 6 0 0  --  
Fi bri n o g e n d ecr e as e - m g/ dL  1 5 0 – 2 0 0  1 2 5 – 1 4 9  1 0 0 – 1 2 4  < 1 0 0 or 
ass oci at e d wit h 
gr oss bl e e di n g 
or diss e mi n at e d 
i ntr a v asc ul ar 
c o a g ul ati o n ( DI C)  
1 T h e l a b or at ory v al u es pr o vi d e d i n t h e t a bl es s erv e as g ui d eli n es a n d ar e d e p e n d e nt u p o n i nstit uti o n al n or m al 
p ar a m et ers. I nstit uti o n al n or m al r ef er e nc e r a n g es s h o ul d b e pr o vi d e d t o d e m o nstr at e t h at t h e y ar e  a p pr o pri at e.  
2 “ UL N” is t h e u p p er li mit of t h e n or m al r a n g e.  
 
Uri n e 1 Mil d ( Gr a d e 1)  M o d er at e 
( Gr a d e 2)  S e v er e ( Gr a d e 3)  P ot e nti all y 
Lif e- 
T hr e at e ni n g 
( Gr a d e 4)  
Pr ot ei n  Tr ac e  1 +  2 +  H os pit aliz ati o n or  
di al ysis  
Gl uc os e  Tr ac e  1 +  2 +  H os pit aliz ati o n 
f or 
h y p er gl yc e mi a  
Bl o o d 
( micr osc o pic) – 
r e d bl o o d c ells 
p er   
hi g h p o w er fi el d (r bc / h pf)  1 - 1 0  1 1 – 5 0  > 5 0 a n d/ or 
gr oss bl o o d  H os pit aliz ati o n 
or p ac k e d r e d 
bl o o d c ells 
( P R B C)  
tr a nsf usi o n  
1 T h e l a b or at ory v al u es pr o vi d e d i n t h e t a bl es s erv e as g ui d eli n es a n d ar e d e p e n d e nt u p o n i nstit uti o n al n or m al 
p ar a m et ers. I nstit uti o n al n or m al r ef er e nc e r a n g es s h o ul d b e pr o vi d e d t o d e m o nstr at e t h at t h e y ar e  a p pr o pri at e.  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 78 of 80 IV. References  
1. National Cancer Institute Common Toxicity Criteria, April 30, 1999. 
(http://ctep.cancer.gov/reporting/CTC-3.html) 
2. Division of AIDS Table for Grading Severity of Adult Adverse Experiences; August 1992. 
(http://rcc.tech -res-intl.com/tox_tables.htm) 
3. The Brighton Collaboration. Finalized Case Definitions and Guidelines. 
(http://brightoncollaboration.org/internet/en/index/definition___guidelines.html) 
4. HIV Vaccine Trials Network Table for Grading Severity of Adverse Experiences; September 18, 2002. (http://rcc.tech -res-intl.com/tox_tables.htm) 
5. Division of AIDS Table for Grading t he Severity of Adult and Pediatric Adverse Events, 
December 2004. 
(http://www3.niaid.nih.gov/research/resources/DAIDSClinRsrch/PDF/Safety/DAIDSAEGradi
ngTable.pdf) 
6. Kratz A, Ferraro M, Sluss PM, Lewandrowski KB. Laboratory Reference Values. New England Journ al of Medicine. 2004;351:1548- 1563.  
 
  
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 79 of 80 10.8 REFERENCES 
 
Azizi H, Mirnajafi- Zadeh J, Rohampour K, Semnanian S. Antagonism of orexin type 1 receptors in 
the locus coeruleus attenuates signs of naloxone -precipitated morphine withdrawal in rats. 
Neurosci Lett. 2010;482:255- 9. 
 
Berger B,
 Kaufmann P, Koch A, Dingemanse J. Impact of the Selective Orexin -1 Rec
eptor 
Antagonist ACT -5393
13 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in 
Healthy Male Subjects. The Journal of Clinical Pharmacology. 2020;60(7 ):931- 41.  
 Coleman
 PJ, Gotter AL, Herring WJ, Winrow CJ, Renger JJ. The discovery of suvorexant, the first 
orexin receptor drug for insomnia. Annu Rev Pharmacol Toxicol. 2017;57:509 -33.  
 Dunn KE, Huhn AS, Bergeria CL, Gipson CD, Weerts EM. Non -Opioid Neurotransmitter Systems 
that Contribute to the Opioid Withdrawal Syndrome: A Review of Preclinical and Human 
Evidence. J Pharmacol Exp Ther. 2019;371:422- 52. 
 
Flockhart DA, Thacker, D., McDonald, C., Desta, Z. The Flockhart Cytochrome P450 Drug -Drug 
Interaction Table. Division of Clinical Pharmacology, Indiana University School of Medicine 
(Updated 2021). Availabe from: https://drug-interactions.medicine.iu.edu/ . Accessed on: 15 
December 2022.  
 
Food and Drug Administration: Drug Development and Drug Interactions: Table of Substrates, 
Inhibitors, and Inducers. Available from:  
https://www.fda.gov/drugs/developmentapprovalprocess/developmentresources/druginteract
ionslabeling/ucm093664.htm. (2022).  Accessed on: 15 December 2022 . 
 
Hooshmand B, Azizi H, Javan M, Semnanian S. Intra- LC microinjection of ore xin type -1 receptor 
antagonist SB -334867 attenuates the expression of glutamate -induced opiate withdrawal like 
signs during the active phase in rats. Neurosci Lett. 2017;636:276 -81. 
 Mahler SV, Smith RJ, Moorman DE, Sartor GC, Aston -Jones G, Multiple roles  for 
orexin/hypocretin in addiction. Prog Brain Res, 2012;198:79 -121.  
 Midazolam hydrochloride (Padagis US, LLC), syrup, full prescribing information (electronic 
monograph; document revised: Aug 2022 ). Available from:  
https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=0be63f63- 6a93- 4782- 8f9c -
d13ca5ae44bd . Accessed on: 15 December 2022. 
 
INDV- 2000  Indivior  
Clinical Study Protocol: INDV- 2000 -104 Final, Amendment 1  10 Apr 2023  
 
Confidential  Page 80 of 80 Misaka S, Kurosawa S, Uchida S, Yoshida A, Kato Y, Kagawa Y, Yamada S. Evaluation of the 
pharmacokinetic interaction of midazolam with ursodeoxycholic acid, ketoconazole and dexamethasone by brain benzodiazepine receptor occupancy. J Pharm Pharmac ol. 
2011;63(1):58- 64.  
 
Murphy P, Moline M, Mayleben D, Rosenberg R, Zammit G, Pinner K, Dhadda S, Hong  Q, Giorgi 
L, Satlin A. Lemborexant, a dual orexin receptor antagonist (DORA) for the  treatment of 
insomnia disorder: results from a Bayesian, adaptive, randomized, doubleblind, placebo-
controlled study. J Clin Sleep Med. 2017;13:1289 -99  
 
Thannickal TC, John J, Shan L; Swaab DF, Wu MF, Ramanathan L, McGregor R, Chew  KT, 
Cornford M, Yamanaka A, Inutsuka A, Fronczek R, Lammers GJ, Worley PF, Siegel JM. Opiates 
increase the number of hypocretin- producing cells in human and mouse  brain and reverse 
cataplexy in a mouse model of narcolepsy. Sci Transl Med.  2018;10:447.  
 Zhou D, Sunzel M, Ribadeneira MD, Smith MA, Desai D, Lin J, Grimm SW. A clinical study to  
assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABAA receptor modulator –an 
in vitro and in vivo comparison. British Journal of Clinical Pharmacology . 2012;74(1):98- 108.  
 